From WikiAlpha
Jump to: navigation, search


Template:Pp-extended {{ safesubst:#invoke:Unsubst||date=__DATE__ |$B= }}Template:Infobox medical condition

Template:COVID-19 pandemic sidebar

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by a virus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019.[1] The disease quickly spread worldwide, resulting in the COVID-19 pandemic.

Symptoms of COVID‑19 are variable, but often include fever,[2] cough, headache,[3] fatigue, breathing difficulties, loss of smell, and loss of taste.[4][5][6] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[7] Of those people who develop symptoms noticeable enough to be classed as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnoea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[8] Older people are at a higher risk of developing severe symptoms. Some people continue to experience a range of effects (long COVID) for months after recovery, and damage to organs has been observed.[9] Multi-year studies are underway to further investigate the long-term effects of the disease.[9]

COVID‑19 transmits when people breathe air contaminated by droplets and small airborne particles containing the virus. The risk of breathing these is highest when people are in close proximity, but they can be inhaled over longer distances, particularly indoors. Transmission can also occur if splashed or sprayed with contaminated fluids in the eyes, nose or mouth, and, rarely, via contaminated surfaces. People remain contagious for up to 20 days, and can spread the virus even if they do not develop symptoms.[10][11]

COVID-19 testing methods to detect the virus's nucleic acid include real-time reverse transcription polymerase chain reaction (rRTTemplate:NbhyphPCR),[12][13] transcription-mediated amplification,[12][13][14] and reverse transcription loop-mediated isothermal amplification (RTTemplate:NbhyphLAMP)[12][13] from a nasopharyngeal swab.[15]

Several COVID-19 vaccines have been approved and distributed in various countries, which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. The use of face masks or coverings has been recommended in public settings to minimise the risk of transmission. While work is underway to develop drugs that inhibit the virus, the primary treatment is symptomatic. Management involves the treatment of symptoms, supportive care, isolation, and experimental measures.

Template:TOC limit


During the initial outbreak in Wuhan, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus",[16][17][18] with the disease sometimes called "Wuhan pneumonia".[19][20] In the past, many diseases have been named after geographical locations, such as the Spanish flu,[21] Middle East respiratory syndrome, and Zika virus.[22] In January 2020, the World Health Organization (WHO) recommended 2019-nCoV[23] and 2019-nCoV acute respiratory disease[24] as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations or groups of people in disease and virus names to prevent social stigma.[25][26][27] The official names COVID‑19 and SARS-CoV-2 were issued by the WHO on 11 February 2020.[28] The Director-General, Tedros Adhanom explained that CO stands for corona, VI for virus, D for disease, and 19 for 2019, the year in which the outbreak was first identified.[29] The WHO additionally uses "the COVID‑19 virus" and "the virus responsible for COVID‑19" in public communications.[28][30]

Signs and symptoms



COVID‑19 is caused by infection with a strain of coronavirus known as 'Severe Acute Respiratory Syndrome coronavirus 2' (SARS-CoV-2).[31]




Severe acute respiratory syndrome coronavirusTemplate:Nbs2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus. It was first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan.[32] All structural features of the novel SARS-CoV-2 virus particle occur in related coronaviruses in nature.[33]

Outside the human body, the virus is destroyed by household soap, which bursts its protective bubble.[34]

SARS-CoV-2 is closely related to the original SARS-CoV.[35] It is thought to have an animal (zoonotic) origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus Betacoronavirus, in subgenus Sarbecovirus (lineage B) together with two bat-derived strains. It is 96% identical at the whole genome level to other bat coronavirus samples (BatCov RaTG13).[36][37][38] The structural proteins of SARS-CoV-2 include membrane glycoprotein (M), envelope protein (E), nucleocapsid protein (N), and the spike protein (S). The M protein of SARS-CoV-2 is about 98% similar to the M protein of bat SARS-CoV, maintains around 98% homology with pangolin SARS-CoV, and has 90% homology with the M protein of SARS-CoV; whereas, the similarity is only around 38% with the M protein of MERS-CoV.[39]

SARS-CoV-2 variants

The many thousands of SARS-CoV-2 variants are grouped into either clades or lineages.[40][41] The WHO, in collaboration with partners, expert networks, national authorities, institutions and researchers, have established nomenclature systems for naming and tracking SARS-CoV-2 genetic lineages by GISAID, Nextstrain and Pango. The expert group convened by the WHO recommended the labelling of variants using letters of the Greek alphabet, for example, Alpha, Beta, Delta, and Gamma, giving the justification that they "will be easier and more practical to discussed by non-scientific audiences."[42] Nextstrain divides the variants into five clades (19A, 19B, 20A, 20B, and 20C), while GISAID divides them into seven (L, O, V, S, G, GH, and GR).[43] The Pango tool groups variants into lineages, with many circulating lineages being classed under the B.1 lineage.[41][44]

Several notable variants of SARS-CoV-2 emerged throughout 2020.[45][46] Cluster 5 emerged among minks and mink farmers in Denmark.[47] After strict quarantines and a mink euthanasia campaign, the cluster was assessed to no longer be circulating among humans in Denmark as of 1 February 2021.[48]

As of December 2021, there are five dominant variants of SARS-CoV-2 spreading among global populations: the Alpha variant (B.1.1.7, formerly called the UK variant), first found in London and Kent, the Beta variant (B.1.351, formerly called the South Africa variant), the Gamma variant (P.1, formerly called the Brazil variant), the Delta variant (B.1.617.2, formerly called the India variant),[49] and the Omicron variant (B.1.1.529), which had spread to 57 countries as of 7 December.[50][51]


The SARS-CoV-2 virus can infect a wide range of cells and systems of the body. COVID‑19 is most known for affecting the upper respiratory tract (sinuses, nose, and throat) and the lower respiratory tract (windpipe and lungs).[52] The lungs are the organs most affected by COVID‑19 because the virus accesses host cells via the receptor for the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant on the surface of type II alveolar cells of the lungs.[53] The virus uses a special surface glycoprotein called a "spike" to connect to the ACE2 receptor and enter the host cell.[54]

Respiratory tract

Following viral entry, COVID‑19 infects the ciliated epithelium of the nasopharynx and upper airways.[55]

Nervous system

One common symptom, loss of smell, results from infection of the support cells of the olfactory epithelium, with subsequent damage to the olfactory neurons.[56] The involvement of both the central and peripheral nervous system in COVID‑19 has been reported in many medical publications.[57] It is clear that many people with COVID-19 exhibit neurological or mental health issues. The virus is not detected in the central nervous system (CNS) of the majority of COVID-19 patients with neurological issues. However, SARS-CoV-2 has been detected at low levels in the brains of those who have died from COVID‑19, but these results need to be confirmed.[58] While virus has been detected in cerebrospinal fluid of autopsies, the exact mechanism by which it invades the CNS remains unclear and may first involve invasion of peripheral nerves given the low levels of ACE2 in the brain.[59][60][61] The virus may also enter the bloodstream from the lungs and cross the blood-brain barrier to gain access to the CNS, possibly within an infected white blood cell.[58]

Research conducted when Alpha was the dominant variant has suggested COVID-19 May cause brain damage. It is unknown if such damage is temporary or permanent, and whether Omicron has similar effects.[62][63] Observed individuals infected with COVID-19 (most with mild cases) experienced an additional 0.2% to 2% of brain tissue lost in regions of the brain connected to the sense of smell compared with uninfected individuals, and the overall effect on the brain was equivalent on average to at least one extra year of normal ageing; infected individuals also scored lower on several cognitive tests. All effects were more pronounced among older ages.[64]

Gastrointestinal tract

The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium[65] as well as endothelial cells and enterocytes of the small intestine.[66]

Cardiovascular system

The virus can cause acute myocardial injury and chronic damage to the cardiovascular system.[67][68] An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China,[69] and is more frequent in severe disease.[70] Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart.[68] ACE2 receptors are highly expressed in the heart and are involved in heart function.[68][71]

A high incidence of thrombosis and venous thromboembolism occurs in people transferred to intensive care units with COVID‑19 infections, and may be related to poor prognosis.[72] Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels caused by blood clots) may have a significant role in mortality, incidencesTemplate:Verify spelling of clots leading to pulmonary embolisms, and ischaemic events within the brain found as complications leading to death in people infected with COVID‑19.[73] Infection may initiate a chain of vasoconstrictive responses within the body, including pulmonary vasoconstriction – a possible mechanism in which oxygenation decreases during pneumonia.[73] Furthermore, damage of arterioles and capillaries was found in brain tissue samples of people who died from COVID‑19.[74][75]

COVID‑19 may also cause substantial structural changes to blood cells, sometimes persisting for months after hospital discharge.[76] A low level of blood lymphocytes may result from the virus acting through ACE2-related entry into lymphocytes.[77]

Other organs

Another common cause of death is complications related to the kidneys.[73] Early reports show that up to 30% of hospitalised patients both in China and in New York have experienced some injury to their kidneys, including some persons with no previous kidney problems.[78]

Autopsies of people who died of COVID‑19 have found diffuse alveolar damage, and lymphocyte-containing inflammatory infiltrates within the lung.[79]


Key components of the adaptive immune response to SARS-CoV-2

Although SARS-CoV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, people with severe COVID‑19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated [[Interleukin 2|ILTemplate:Nbh2]], [[Interleukin 7|ILTemplate:Nbh7]], [[Interleukin 6|ILTemplate:Nbh6]], granulocyte-macrophage colony-stimulating factor (GMTemplate:NbhCSF), [[CXCL10|interferon gamma-induced proteinTemplate:Nbs10]] (IPTemplate:Nbh10), [[Monocyte chemoattractant protein-1|monocyte chemoattractant proteinTemplate:Nbs1]] (MCP1), [[CCL3|macrophage inflammatory protein 1Template:Nbhalpha]] (MIPTemplate:Nbh1Template:Nbhalpha), and tumour necrosis factor (TNFTemplate:Nbhα) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology.[69]

Additionally, people with COVID‑19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin.[80]

Systemic inflammation results in vasodilation, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in people with COVID‑19.[81] Lymphocytic infiltrates have also been reported at autopsy.[79]

Viral and host factors

Virus proteins

The association between SARS-CoV-2 and the Renin-Angiotensin-Aldosterone System (RAAS)

Multiple viral and host factors affect the pathogenesis of the virus. The S-protein, otherwise known as the spike protein, is the viral component that attaches to the host receptor via the ACE2 receptors. It includes two subunits: S1 and S2. S1 determines the virus-host range and cellular tropism via the receptor-binding domain. S2 mediates the membrane fusion of the virus to its potential cell host via the H1 and HR2, which are heptad repeat regions. Studies have shown that S1 domain induced IgG and IgA antibody levels at a much higher capacity. It is the focus spike proteins expression that are involved in many effective COVID‑19 vaccines.[82]

The M protein is the viral protein responsible for the transmembrane transport of nutrients. It is the cause of the bud release and the formation of the viral envelope.[83] The N and E protein are accessory proteins that interfere with the host's immune response.[83]

Host factors

Human angiotensin converting enzyme 2 (hACE2) is the host factor that SARS-CoV-2 virus targets causing COVID‑19. Theoretically, the usage of angiotensin receptor blockers (ARB) and ACE inhibitors upregulating ACE2 expression might increase morbidity with COVID‑19, though animal data suggest some potential protective effect of ARB; however no clinical studies have proven susceptibility or outcomes. Until further data is available, guidelines and recommendations for hypertensive patients remain.[84]

The effect of the virus on ACE2 cell surfaces leads to leukocytic infiltration, increased blood vessel permeability, alveolar wall permeability, as well as decreased secretion of lung surfactants. These effects cause the majority of the respiratory symptoms. However, the aggravation of local inflammation causes a cytokine storm eventually leading to a systemic inflammatory response syndrome.[85]

Among healthy adults not exposed to SARS-CoV-2, about 35% have CD4+ T cells that recognise the SARS-CoV-2 S protein (particularly the S2 subunit) and about 50% react to other proteins of the virus, suggesting cross-reactivity from previous common colds caused by other coronaviruses.[86]

It is unknown whether different persons use similar antibody genes in response to COVID‑19.[87]

Host cytokine response

The severity of the inflammation can be attributed to the severity of what is known as the cytokine storm.[88] Levels of [[Interleukin 1 beta|interleukinTemplate:Nbs1B]], interferon-gamma, interferon-inducible protein 10, and monocyte chemoattractant proteinTemplate:Nbs1 were all associated with COVID‑19 disease severity. Treatment has been proposed to combat the cytokine storm as it remains to be one of the leading causes of morbidity and mortality in COVID‑19 disease.[89]

A cytokine storm is due to an acute hyperinflammatory response that is responsible for clinical illness in an array of diseases but in COVID‑19, it is related to worse prognosis and increased fatality. The storm causes acute respiratory distress syndrome, blood clotting events such as strokes, myocardial infarction, encephalitis, acute kidney injury, and vasculitis. The production of IL-1, IL-2, IL-6, TNF-alpha, and interferon-gamma, all crucial components of normal immune responses, inadvertently become the causes of a cytokine storm. The cells of the central nervous system, the microglia, neurons, and astrocytes, are also involved in the release of pro-inflammatory cytokines affecting the nervous system, and effects of cytokine storms toward the CNS are not uncommon.[90]

Pregnancy response

There are many unknowns for pregnant women during the COVID-19 pandemic. Given that they are prone to have complications and severe disease infection with other types of coronaviruses, they have been identified as a vulnerable group and advised to take supplementary preventive measures.[91]

Physiological responses to pregnancy can include:

  • Immunological: The immunological response to COVID-19, like other viruses, depends on a working immune system. It adapts during pregnancy to allow the development of the foetus whose genetic load is only partially shared with their mother, leading to a different immunological reaction to infections during the course of pregnancy.[91]
  • Respiratory: Many factors can make pregnant women more vulnerable to hard respiratory infections. One of them is the total reduction of the lungs' capacity and inability to clear secretions.[91]
  • Coagulation: During pregnancy, there are higher levels of circulating coagulation factors, and the pathogenesis of SARS-CoV-2 infection can be implicated. The thromboembolic events with associated mortality are a risk for pregnant women.[91]

However, from the evidence base, it is difficult to conclude whether pregnant women are at increased risk of grave consequences of this virus.[91]

In addition to the above, other clinical studies have proved that SARS-CoV-2 can affect the period of pregnancy in different ways. On the one hand, there is little evidence of its impact up to 12 weeks gestation. On the other hand, COVID-19 infection may cause increased rates of unfavourable outcomes in the course of the pregnancy. Some examples of these could be foetal growth restriction, preterm birth, and perinatal mortality, which refers to the foetal death past 22 or 28 completed weeks of pregnancy as well as the death among live-born children up to seven completed days of life.[91]

Unvaccinated women in later stages of pregnancy with COVID-19 are more likely than other patients to need very intensive care. Babies born to mothers with COVID-19 are more likely to have breathing problems. Pregnant women are strongly encouraged to get vaccinated.[92]


COVID‑19 can provisionally be diagnosed on the basis of symptoms and confirmed using reverse transcription polymerase chain reaction (RT-PCR) or other nucleic acid testing of infected secretions.[15][93] Along with laboratory testing, chest CT scans may be helpful to diagnose COVID‑19 in individuals with a high clinical suspicion of infection.[94] Detection of a past infection is possible with serological tests, which detect antibodies produced by the body in response to the infection.[15]

Viral testing

The standard methods of testing for presence of SARS-CoV-2 are nucleic acid tests,[15][95] which detects the presence of viral RNA fragments.[96] As these tests detect RNA but not infectious virus, its "ability to determine duration of infectivity of patients is limited."[97] The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used.[98][99] Results are generally available within hours.[15] The WHO has published several testing protocols for the disease.[100]

Several laboratories and companies have developed serological tests, which detect antibodies produced by the body in response to infection. Several have been evaluated by Public Health England and approved for use in the UK.[101]

The University of Oxford's CEBM has pointed to mounting evidence[102][103] that "a good proportion of 'new' mild cases and people re-testing positives after quarantine or discharge from hospital are not infectious, but are simply clearing harmless virus particles which their immune system has efficiently dealt with" and have called for "an international effort to standardize and periodically calibrate testing"[104] In September 2020, the UK government issued "guidance for procedures to be implemented in laboratories to provide assurance of positive SARS-CoV-2 RNA results during periods of low prevalence, when there is a reduction in the predictive value of positive test results".[105]


A CT scan of a person with COVID-19 shows lesions (bright regions) in the lungs
CT scan of rapid progression stage of COVID-19
File:COVID-19 Pneumonie - 82m Roe Thorax ap - 001.jpg
Chest X-ray showing COVID‑19 pneumonia

Chest CT scans may be helpful to diagnose COVID‑19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening.[94][106] Bilateral multilobar ground-glass opacities with a peripheral, asymmetric, and posterior distribution are common in early infection.[94][107] Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses.[94][108] Characteristic imaging features on chest radiographs and computed tomography (CT) of people who are symptomatic include asymmetric peripheral ground-glass opacities without pleural effusions.[109]

Many groups have created COVID‑19 datasets that include imagery such as the Italian Radiological Society which has compiled an international online database of imaging findings for confirmed cases.[110] Due to overlap with other infections such as adenovirus, imaging without confirmation by rRT-PCR is of limited specificity in identifying COVID‑19.[109] A large study in China compared chest CT results to PCR and demonstrated that though imaging is less specific for the infection, it is faster and more sensitive.[93]


In late 2019, the WHO assigned emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID‑19 without lab-confirmed SARS-CoV-2 infection.[111]


The main pathological findings at autopsy are:


File:20200609 Effect of pandemic containment measures.gif
Without pandemic containment measuresTemplate:Sndsuch as social distancing, vaccination, and face masksTemplate:Sndpathogens can spread exponentially.[116] This graphic shows how early adoption of containment measures tends to protect wider swaths of the population.

Preventive measures to reduce the chances of infection include getting vaccinated, staying at home, wearing a mask in public, avoiding crowded places, keeping distance from others, ventilating indoor spaces, managing potential exposure durations,[117] washing hands with soap and water often and for at least twenty seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands.[118][119]

Those diagnosed with COVID‑19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items.[120][121]

The first COVID‑19 vaccine was granted regulatory approval on 2Template:NbsDecember 2020 by the UK medicines regulator MHRA.[122] It was evaluated for emergency use authorization (EUA) status by the US FDA, and in several other countries.[123] Initially, the US National Institutes of Health guidelines do not recommend any medication for prevention of COVID‑19, before or after exposure to the SARS-CoV-2 virus, outside the setting of a clinical trial.[124][125] Without a vaccine, other prophylactic measures, or effective treatments, a key part of managing COVID‑19 is trying to decrease and delay the epidemic peak, known as "flattening the curve".[126] This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of active cases, and delaying additional cases until effective treatments or a vaccine become available.[126][127]


Different vaccine candidate types in development for SARS-CoV-2


Face masks and respiratory hygiene

Masks with an exhalation valve. The valves are a weak point that can transmit the viruses outwards.

The WHO and the US CDC recommend individuals wear non-medical face coverings in public settings where there is an increased risk of transmission and where social distancing measures are difficult to maintain.[128][129] This recommendation is meant to reduce the spread of the disease by asymptomatic and pre-symptomatic individuals and is complementary to established preventive measures such as social distancing.[129][130] Face coverings limit the volume and travel distance of expiratory droplets dispersed when talking, breathing, and coughing.[129][130] A face covering without vents or holes will also filter out particles containing the virus from inhaled and exhaled air, reducing the chances of infection.[131] But, if the mask include an exhalation valve, a wearer that is infected (maybe without having noticed that, and asymptomatic) would transmit the virus outwards through it, despite any certification they can have. So the masks with exhalation valve are not for the infected wearers, and are not reliable to stop the pandemic in a large scale. Many countries and local jurisdictions encourage or mandate the use of face masks or cloth face coverings by members of the public to limit the spread of the virus.[132]

Masks are also strongly recommended for those who may have been infected and those taking care of someone who may have the disease.[133] When not wearing a mask, the CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available. Proper hand hygiene after any cough or sneeze is encouraged. Healthcare professionals interacting directly with people who have COVID‑19 are advised to use respirators at least as protective as NIOSH-certified N95 or equivalent, in addition to other personal protective equipment.[134]

Indoor ventilation and avoiding crowded indoor spaces

The CDC recommends that crowded indoor spaces should be avoided.[135] When indoors, increasing the rate of air change, decreasing recirculation of air and increasing the use of outdoor air can reduce transmission.[135][136] The WHO recommends ventilation and air filtration in public spaces to help clear out infectious aerosols.[137][138][139]

Exhaled respiratory particles can build-up within enclosed spaces with inadequate ventilation. The risk of COVID‑19 infection increases especially in spaces where people engage in physical exertion or raise their voice (e.g., exercising, shouting, singing) as this increases exhalation of respiratory droplets. Prolonged exposure to these conditions, typically more than 15 minutes, leads to higher risk of infection.[135]

Displacement ventilation with large natural inlets can move stale air directly to the exhaust in laminar flow while significantly reducing the concentration of droplets and particles. Passive ventilation reduces energy consumption and maintenance costs but may lack controllability and heat recovery. Displacement ventilation can also be achieved mechanically with higher energy and maintenance costs. The use of large ducts and openings helps to prevent mixing in closed environments. Recirculation and mixing should be avoided because recirculation prevents dilution of harmful particles and redistributes possibly contaminated air, and mixing increases the concentration and range of infectious particles and keeps larger particles in the air.[140]

Hand-washing and hygiene

Thorough hand hygiene after any cough or sneeze is required.[141] The WHO also recommends that individuals wash hands often with soap and water for at least twenty seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose.[142] When soap and water are not available, the CDC recommends using an alcohol-based hand sanitiser with at least 60% alcohol.[143] For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol or isopropanol. Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis." Glycerol is added as a humectant.[144]

Social distancing

Social distancing (also known as physical distancing) includes infection control actions intended to slow the spread of the disease by minimising close contact between individuals. Methods include quarantines; travel restrictions; and the closing of schools, workplaces, stadiums, theatres, or shopping centres. Individuals may apply social distancing methods by staying at home, limiting travel, avoiding crowded areas, using no-contact greetings, and physically distancing themselves from others.[145] Many governments are mandating or recommending social distancing in regions affected by the outbreak.[146]

Outbreaks have occurred in prisons due to crowding and an inability to enforce adequate social distancing.[147][148] In the United States, the prisoner population is ageing and many of them are at high risk for poor outcomes from COVID‑19 due to high rates of coexisting heart and lung disease, and poor access to high-quality healthcare.[147]

Surface cleaning

After being expelled from the body, coronaviruses can survive on surfaces for hours to days. If a person touches the dirty surface, they may deposit the virus at the eyes, nose, or mouth where it can enter the body and cause infection.[149] Evidence indicates that contact with infected surfaces is not the main driver of COVID‑19,[150][151][152] leading to recommendations for optimised disinfection procedures to avoid issues such as the increase of antimicrobial resistance through the use of inappropriate cleaning products and processes.[153][154] Deep cleaning and other surface sanitation has been criticised as hygiene theatre, giving a false sense of security against something primarily spread through the air.[155][156]

The amount of time that the virus can survive depends significantly on the type of surface, the temperature, and the humidity.[157] Coronaviruses die very quickly when exposed to the UV light in sunlight.[157] Like other enveloped viruses, SARS-CoV-2 survives longest when the temperature is at room temperature or lower, and when the relative humidity is low (<50%).[157]

On many surfaces, including glass, some types of plastic, stainless steel, and skin, the virus can remain infective for several days indoors at room temperature, or even about a week under ideal conditions.[157][158] On some surfaces, including cotton fabric and copper, the virus usually dies after a few hours.[157] The virus dies faster on porous surfaces than on non-porous surfaces due to capillary action within pores and faster aerosol droplet evaporation.[159][152][157] However, of the many surfaces tested, two with the longest survival times are N95 respirator masks and surgical masks, both of which are considered porous surfaces.[157]

The CDC says that in most situations, cleaning surfaces with soap or detergent, not disinfecting, is enough to reduce risk of transmission.[160][161] The CDC recommends that if a COVID‑19 case is suspected or confirmed at a facility such as an office or day care, all areas such as offices, bathrooms, common areas, shared electronic equipment like tablets, touch screens, keyboards, remote controls, and ATMs used by the ill persons should be disinfected.[162] Surfaces may be decontaminated with 62–71 per cent ethanol, 50–100 per cent isopropanol, 0.1 per cent sodium hypochlorite, 0.5 per cent hydrogen peroxide, 0.2–7.5 per cent povidone-iodine, or 50–200 ppm hypochlorous acid. Other solutions, such as benzalkonium chloride and chlorhexidine gluconate, are less effective. Ultraviolet germicidal irradiation may also be used,[137] although popular devices require Template:Val exposure and may deteriorate some materials over time.[163] A datasheet comprising the authorised substances to disinfection in the food industry (including suspension or surface tested, kind of surface, use dilution, disinfectant and inocuylum volumes) can be seen in the supplementary material of.[153]


Self-isolation at home has been recommended for those diagnosed with COVID‑19 and those who suspect they have been infected. Health agencies have issued detailed instructions for proper self-isolation.[164] Many governments have mandated or recommended self-quarantine for entire populations. The strongest self-quarantine instructions have been issued to those in high-risk groups.[165] Those who may have been exposed to someone with COVID‑19 and those who have recently travelled to a country or region with the widespread transmission have been advised to self-quarantine for 14 days from the time of last possible exposure.[166]

Healthy diet and lifestyle

The Harvard T.H. Chan School of Public Health recommends a healthy diet, being physically active, managing psychological stress, and getting enough sleep.[167]

Consistently meeting scientific guidelines of 150+ minutes per week of exercise or similar physical activity was shown to be associated with a smaller risk of hospitalisation and death due to COVID‑19, even when considering likely risk factors such as elevated Body mass index (BMI).[168][169]

A meta-analysis, published online in October 2021, concluded that "Vitamin D supplementation in SARS-CoV-2 positive patients has the potential to positively impact patients with both mild and severe symptoms."[170] The largest observational study on the subject using online questionnaires, with over 6,000 participants and a dosage regime near the RDI, is set to conclude in July 2021.[171][172] One of the collaborators in the study is Synergy Biologics Ltd, a manufacturer of vitamin D3 supplements.[172]

International travel-related control measures

A 2021 Cochrane rapid review found that based upon low-certainty evidence, international travel-related control measures such as restricting cross-border travel may help to contain the spread of COVID‑19.[173] Additionally, symptom/exposure-based screening measures at borders may miss many positive cases.[173] While test-based border screening measures may be more effective, it could also miss many positive cases if only conducted upon arrival without follow-up. The review concluded that a minimum 10-day quarantine may be beneficial in preventing the spread of COVID‑19 and may be more effective if combined with an additional control measure like border screening.[173]


File:An overview of COVID-19 therapeutics and drugs.webp
An overview of COVID-19 therapeutics and drugs


Prognosis and risk factors

The severity of COVID‑19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. In 3–4% of cases (7.4% for those over age 65) symptoms are severe enough to cause hospitalisation.[174] Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks.[36] The Italian Istituto Superiore di Sanità reported that the median time between the onset of symptoms and death was twelve days, with seven being hospitalised. However, people transferred to an ICU had a median time of ten days between hospitalisation and death.[175] Abnormal sodium levels during hospitalization with COVID-19 are associated with poor prognoses: high sodium with a greater risk of death, and low sodium with an increased chance of needing ventilator support.[176][177] Prolonged prothrombin time and elevated C-reactive protein levels on admission to the hospital are associated with severe course of COVID‑19 and with a transfer to ICU.[178][179]

Some early studies suggest 10% to 20% of people with COVID‑19 will experience symptoms lasting longer than a month.[180][181] A majority of those who were admitted to hospital with severe disease report long-term problems including fatigue and shortness of breath.[182] On 30 October 2020, WHO chief Tedros Adhanom warned that "to a significant number of people, the COVID virus poses a range of serious long-term effects." He has described the vast spectrum of COVID‑19 symptoms that fluctuate over time as "really concerning". They range from fatigue, a cough and shortness of breath, to inflammation and injury of major organsTemplate:Sndincluding the lungs and heart, and also neurological and psychologic effects. Symptoms often overlap and can affect any system in the body. Infected people have reported cyclical bouts of fatigue, headaches, months of complete exhaustion, mood swings, and other symptoms. Tedros therefore concluded that a strategy of achieving herd immunity by infection, rather than vaccination, is "morally unconscionable and unfeasible".[183]

In terms of hospital readmissions about 9% of 106,000 individuals had to return for hospital treatment within two months of discharge. The average to readmit was eight days since first hospital visit. There are several risk factors that have been identified as being a cause of multiple admissions to a hospital facility. Among these are advanced age (above 65 years of age) and presence of a chronic condition such as diabetes, COPD, heart failure or chronic kidney disease.[184][185]

According to scientific reviews smokers are more likely to require intensive care or die compared to non-smokers.[186][187] Acting on the same ACE2 pulmonary receptors affected by smoking, air pollution has been correlated with the disease.[187] Short term[188] and chronic[189] exposure to air pollution seems to enhance morbidity and mortality from COVID‑19.[190][191][192] Pre-existing heart and lung diseases[193] and also obesity, especially in conjunction with fatty liver disease, contributes to an increased health risk of COVID‑19.[187][194][195][196]

It is also assumed that those that are immunocompromised are at higher risk of getting severely sick from SARS-CoV-2.[197] One research study that looked into the COVID‑19 infections in hospitalised kidney transplant recipients found a mortality rate of 11%.[198]

Genetics also plays an important role in the ability to fight off the disease.[199] For instance, those that do not produce detectable type I interferons or produce auto-antibodies against these may get much sicker from COVID‑19.[200][201] Genetic screening is able to detect interferon effector genes.[202]

Men with untreated hypogonadism were 2.4 times more likely than men with eugonadism to be hospitalized if they contracted COVID-19; Hypogonad men treated with testosterone were less likely to be hospitalized for COVID-19 than men who were not treated for hypogonadism.[203]


While very young children have experienced lower rates of infection, older children have a rate of infection that is similar to the population as a whole.[204][205] Children are likely to have milder symptoms and are at lower risk of severe disease than adults.[206] The CDC reports that in the US roughly a third of hospitalised children were admitted to the ICU,[207] while a European multinational study of hospitalised children from June 2020, found that about 8% of children admitted to a hospital needed intensive care.[208] Four of the 582 children (0.7%) in the European study died, but the actual mortality rate may be "substantially lower" since milder cases that did not seek medical help were not included in the study.[209][210]


Mechanisms of SARS-CoV-2 cytokine storm and complications

Complications may include pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, septic shock, and death.[211][212][213][214] Cardiovascular complications may include heart failure, arrhythmias (including atrial fibrillation), heart inflammation, and thrombosis, particularly venous thromboembolism.[215][216][217][218][219][220] Approximately 20–30% of people who present with COVID‑19 have elevated liver enzymes, reflecting liver injury.[221][125]

Neurologic manifestations include seizure, stroke, encephalitis, and Guillain–Barré syndrome (which includes loss of motor functions).[222][223] Following the infection, children may develop paediatric multisystem inflammatory syndrome, which has symptoms similar to Kawasaki disease, which can be fatal.[224][225] In very rare cases, acute encephalopathy can occur, and it can be considered in those who have been diagnosed with COVID‑19 and have an altered mental status.[226]

In the case of pregnant women, it is important to note that, according to the US Centers for Disease Control and Prevention, pregnant women are at increased risk of becoming seriously ill from COVID‑19.[227] This is because pregnant women with COVID‑19 appear to be more likely to develop respiratory and obstetric complications that can lead to miscarriage, premature delivery and intrauterine growth restriction.[227]

Fungal infections such as aspergillosis, candidiasis, cryptococcosis and mucormycosis have been recorded in patients recovering from COVID‑19.[228][229]

Longer-term effects

Some early studies suggest that 10–20% of people with COVID‑19 will experience symptoms lasting longer than a month.[230][181] A majority of those who were admitted to hospital with severe disease report long-term problems, including fatigue and shortness of breath.[231] About 5–10% of patients admitted to hospital progress to severe or critical disease, including pneumonia and acute respiratory failure.[232]

By a variety of mechanisms, the lungs are the organs most affected in COVID‑19.[233] In people requiring hospital admission, up to 98% of CT scans performed show lung abnormalities after 28 days of illness even if they had clinically improved.[234]

People with advanced age, severe disease, prolonged ICU stays, or who smoke are more likely to have long-lasting effects, including pulmonary fibrosis.[235] Overall, approximately one-third of those investigated after four weeks will have findings of pulmonary fibrosis or reduced lung function as measured by DLCO, even in asymptomatic people, but with the suggestion of continuing improvement with the passing of more time.[233] After severe disease, lung function can take anywhere from three months to a year or more to return to previous levels.[236]

The risks of cognitive deficit, dementia, psychotic disorders, and epilepsy or seizures persists at an increased level two years after infection.[237]


The immune response by humans to SARS-CoV-2 virus occurs as a combination of the cell-mediated immunity and antibody production,[238] just as with most other infections.[239] B cells interact with T cells and begin dividing before selection into the plasma cell, partly on the basis of their affinity for antigen.[240] Since SARS-CoV-2 has been in the human population only since December 2019, it remains unknown if the immunity is long-lasting in people who recover from the disease.[241] The presence of neutralising antibodies in blood strongly correlates with protection from infection, but the level of neutralising antibody declines with time. Those with asymptomatic or mild disease had undetectable levels of neutralising antibody two months after infection. In another study, the level of neutralising antibodies fell four-fold one to four months after the onset of symptoms. However, the lack of antibodies in the blood does not mean antibodies will not be rapidly produced upon reexposure to SARS-CoV-2. Memory B cells specific for the spike and nucleocapsid proteins of SARS-CoV-2 last for at least six months after the appearance of symptoms.[241]

As of August 2021, reinfection with COVID‑19 was possible but uncommon. The first case of reinfection was documented in August 2020.[242] A systematic review found 17 cases of confirmed reinfection in medical literature as of May 2021.[242] With the Omicron variant, as of 2022, reinfections have become common, albeit it is unclear how common.[243] COVID-19 reinfections are thought to likely be less severe than primary infections, especially if one was previously infected by the same variant.[243]Template:Additional citation needed


Several measures are commonly used to quantify mortality.[244] These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health.[245]

The mortality rate reflects the number of deaths within a specific demographic group divided by the population of that demographic group. Consequently, the mortality rate reflects the prevalence as well as the severity of the disease within a given population. Mortality rates are highly correlated to age, with relatively low rates for young people and relatively high rates among the elderly.[246][247][248] In fact, one relevant factor of mortality rates is the age structure of the countries' populations. For example, the case fatality rate for COVID‑19 is lower in India than in the US since India's younger population represents a larger percentage than in the US.[249]

Case fatality rate

The case fatality rate (CFR) reflects the number of deaths divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is Template:Cases in the COVID-19 pandemic (Template:Cases in the COVID-19 pandemic/Template:Cases in the COVID-19 pandemic) as of Template:Cases in the COVID-19 pandemic.Template:Cases in the COVID-19 pandemic The number varies by region.[250][251]

Infection fatality rate

A key metric in gauging the severity of COVID‑19 is the infection fatality rate (IFR), also referred to as the infection fatality ratio or infection fatality risk.[254][255][256] This metric is calculated by dividing the total number of deaths from the disease by the total number of infected individuals; hence, in contrast to the CFR, the IFR incorporates asymptomatic and undiagnosed infections as well as reported cases.[257]


File:Graph of Covid-19 Infection Fatality Ratio by age.png
The red line shows the estimate of infection fatality rate (IFR), in percentage terms, as a function of age. The shaded region depicts the 95% confidence interval for that estimate. Markers denotes specific observations used in the meta-analysis.[258]
File:Log Graph of Covid-19 Infection Fatality Ratio by age.png
The same relationship plotted on a log scale

A December 2020 systematic review and meta-analysis estimated that population IFR during the first wave of the pandemic was about 0.5% to 1% in many locations (including France, Netherlands, New Zealand, and Portugal), 1% to 2% in other locations (Australia, England, Lithuania, and Spain), and exceeded 2% in Italy.[258] That study also found that most of these differences in IFR reflected corresponding differences in the age composition of the population and age-specific infection rates; in particular, the metaregression estimate of IFR is very low for children and younger adults (e.g., 0.002% at age 10 and 0.01% at age 25) but increases progressively to 0.4% at age 55, 1.4% at age 65, 4.6% at age 75, and 15% at age 85.[258] These results were also highlighted in a December 2020 report issued by the WHO.[259]

IFR estimate per age group
(to December 2020)
Age group IFR
0–34 0.004%
35–44 0.068%
45–54 0.23%
55–64 0.75%
65–74 2.5%
75–84 8.5%
85 + 28.3%

An analysis of those IFR rates indicates that COVID‑19 is hazardous not only for the elderly but also for middle-aged adults, for whom the infection fatality rate of COVID-19 is two orders of magnitude greater than the annualised risk of a fatal automobile accident and far more dangerous than seasonal influenza.[258]

Earlier estimates of IFR

At an early stage of the pandemic, the World Health Organization reported estimates of IFR between 0.3% and 1%.[260][261] On 2Template:NbsJuly, The WHO's chief scientist reported that the average IFR estimate presented at a two-day WHO expert forum was about 0.6%.[262][263] In August, the WHO found that studies incorporating data from broad serology testing in Europe showed IFR estimates converging at approximately 0.5–1%.[264] Firm lower limits of IFRs have been established in a number of locations such as New York City and Bergamo in Italy since the IFR cannot be less than the population fatality rate. (After sufficient time however, people can get reinfected).[265] As of 10 July, in New York City, with a population of 8.4 million, 23,377 individuals (18,758 confirmed and 4,619 probable) have died with COVID‑19 (0.3% of the population).[266] Antibody testing in New York City suggested an IFR of ~0.9%,[267] and ~1.4%.[268] In Bergamo province, 0.6% of the population has died.[269] In September 2020, the U.S. Centers for Disease Control and Prevention (CDC) reported preliminary estimates of age-specific IFRs for public health planning purposes.[270]

Sex differences

COVID‑19 case fatality rates are higher among men than women in most countries. However, in a few countries like India, Nepal, Vietnam, and Slovenia the fatality cases are higher in women than men.[249] Globally, men are more likely to be admitted to the ICU and more likely to die.[272][273] One meta-analysis found that globally, men were more likely to get COVID‑19 than women; there were approximately 55 men and 45 women per 100 infections (CI: 51.43–56.58).[274]

The Chinese Center for Disease Control and Prevention reported the death rate was 2.8% for men and 1.7% for women.[275] Later reviews in June 2020 indicated that there is no significant difference in susceptibility or in CFR between genders.[276][277] One review acknowledges the different mortality rates in Chinese men, suggesting that it may be attributable to lifestyle choices such as smoking and drinking alcohol rather than genetic factors.[278] Smoking, which in some countries like China is mainly a male activity, is a habit that contributes to increasing significantly the case fatality rates among men.[249] Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.[279] In Europe as of February 2020, 57% of the infected people were men and 72% of those died with COVID‑19 were men.[280] As of April 2020, the US government is not tracking sex-related data of COVID‑19 infections.[281] Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.[281]

Ethnic differences

In the US, a greater proportion of deaths due to COVID‑19 have occurred among African Americans and other minority groups.[282] Structural factors that prevent them from practising social distancing include their concentration in crowded substandard housing and in "essential" occupations such as retail grocery workers, public transit employees, health-care workers and custodial staff. Greater prevalence of lacking health insurance and care of underlying conditions such as diabetes, hypertension, and heart disease also increase their risk of death.[283] Similar issues affect Native American and Latino communities.[282] On the one hand, in the Dominican Republic there is a clear example of both gender and ethnic inequality. In this Latin American territory, there is great inequality and precariousness that especially affects Dominican women, with greater emphasis on those of Haitian descent.[284] According to a US health policy non-profit, 34% of American Indian and Alaska Native People (AIAN) non-elderly adults are at risk of serious illness compared to 21% of white non-elderly adults.[285] The source attributes it to disproportionately high rates of many health conditions that may put them at higher risk as well as living conditions like lack of access to clean water.[286]

Leaders have called for efforts to research and address the disparities.[287] In the UK, a greater proportion of deaths due to COVID‑19 have occurred in those of a Black, Asian, and other ethnic minority background.[288][289][290] More severe impacts upon patients including the relative incidence of the necessity of hospitalisation requirements, and vulnerability to the disease has been associated via DNA analysis to be expressed in genetic variants at chromosomal region 3, features that are associated with European Neanderthal heritage. That structure imposes greater risks that those affected will develop a more severe form of the disease.[291] The findings are from Professor Svante Pääbo and researchers he leads at the Max Planck Institute for Evolutionary Anthropology and the Karolinska Institutet.[291] This admixture of modern human and Neanderthal genes is estimated to have occurred roughly between 50,000 and 60,000 years ago in Southern Europe.[291]


Biological factors (immune response) and the general behaviour (habits) can strongly determine the consequences of COVID‑19.[249] Most of those who die of COVID‑19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease.[292] According to March data from the United States, 89% of those hospitalised had preexisting conditions.[293] The Italian Istituto Superiore di Sanità reported that out of 8.8% of deaths where medical charts were available, 96.1% of people had at least one comorbidity with the average person having 3.4 diseases.[175] According to this report the most common comorbidities are hypertension (66% of deaths), type 2 diabetes (29.8% of deaths), ischaemic heart disease (27.6% of deaths), atrial fibrillation (23.1% of deaths) and chronic renal failure (20.2% of deaths).

Most critical respiratory comorbidities according to the US Centers for Disease Control and Prevention (CDC), are: moderate or severe asthma, pre-existing COPD, pulmonary fibrosis, cystic fibrosis.[294] Evidence stemming from meta-analysis of several smaller research papers also suggests that smoking can be associated with worse outcomes.[295][296] When someone with existing respiratory problems is infected with COVID‑19, they might be at greater risk for severe symptoms.[297] COVID‑19 also poses a greater risk to people who misuse opioids and methamphetamines, insofar as their drug use may have caused lung damage.[298]

In August 2020, the CDC issued a caution that tuberculosis (TB) infections could increase the risk of severe illness or death. The WHO recommended that people with respiratory symptoms be screened for both diseases, as testing positive for COVID‑19 could not rule out co-infections. Some projections have estimated that reduced TB detection due to the pandemic could result in 6.3 million additional TB cases and 1.4 million TB-related deaths by 2025.[299]


The virus is thought to be of natural animal origin, most likely through spillover infection.[33][300][301] A joint-study conducted in early 2021 by the People's Republic of China and the World Health Organization indicated that the virus descended from a coronavirus that infects wild bats, and likely spread to humans through an intermediary wildlife host.[302] There are several theories about where the index case originated and investigations into the origin of the pandemic are ongoing.[303] According to articles published in July 2022 in Science, virus transmission into humans occurred through two spillover events in November 2019 and was likely due to live wildlife trade on the Huanan wet market in the city of Wuhan (Hubei, China).[304][305][306] Doubts about the conclusions have mostly centred on the precise site of spillover.[307] Earlier phylogenetics estimated that SARS-CoV-2 arose in October or November 2019.[308][309][310] A phylogenetic algorithm analysis suggested that the virus may have been circulating in Guangdong before Wuhan.[311] The possibility that the virus was accidentally released from a laboratory has also been under consideration.[312] U.S intelligence agencies found that the virus was not developed as a biological weapon and that it is unlikely for it to have been genetically engineered.[313]

The first confirmed human infections were in Wuhan. A study of the first 41 cases of confirmed COVID‑19, published in January 2020 in The Lancet, reported the earliest date of onset of symptoms as 1Template:NbsDecember 2019.[314][315][316] Official publications from the WHO reported the earliest onset of symptoms as 8Template:NbsDecember 2019.[317] Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020.[318][319] According to official Chinese sources, these were mostly linked to the Huanan Seafood Wholesale Market, which also sold live animals.[320] In May 2020, George Gao, the director of the CDC, said animal samples collected from the seafood market had tested negative for the virus, indicating that the market was the site of an early superspreading event, but that it was not the site of the initial outbreak.[321] Traces of the virus have been found in wastewater samples that were collected in Milan and Turin, Italy, on 18 December 2019.[322]

By December 2019, the spread of infection was almost entirely driven by human-to-human transmission.[323][324] The number of COVID-19 cases in Hubei gradually increased, reaching sixty by 20 December,[325] and at least 266 by 31 December.[326] On 24 December, Wuhan Central Hospital sent a bronchoalveolar lavage fluid (BAL) sample from an unresolved clinical case to sequencing company Vision Medicals. On 27 and 28 December, Vision Medicals informed the Wuhan Central Hospital and the Chinese CDC of the results of the test, showing a new coronavirus.[327] A pneumonia cluster of unknown cause was observed on 26 December and treated by the doctor Zhang Jixian in Hubei Provincial Hospital, who informed the Wuhan Jianghan CDC on 27 December.[328] On 30 December, a test report addressed to Wuhan Central Hospital, from company CapitalBio Medlab, stated an erroneous positive result for SARS, causing a group of doctors at Wuhan Central Hospital to alert their colleagues and relevant hospital authorities of the result. The Wuhan Municipal Health Commission issued a notice to various medical institutions on "the treatment of pneumonia of unknown cause" that same evening.[329] Eight of these doctors, including Li Wenliang (punished on 3Template:NbsJanuary),[330] were later admonished by the police for spreading false rumours and another, Ai Fen, was reprimanded by her superiors for raising the alarm.[331]

The Wuhan Municipal Health Commission made the first public announcement of a pneumonia outbreak of unknown cause on 31 December, confirming 27 cases[332][333][334]Template:Sndenough to trigger an investigation.[335]

During the early stages of the outbreak, the number of cases doubled approximately every seven and a half days.[336] In early and mid-January 2020, the virus spread to other Chinese provinces, helped by the Chinese New Year migration and Wuhan being a transport hub and major rail interchange.[36] On 20 January, China reported nearly 140 new cases in one day, including two people in Beijing and one in Shenzhen.[337] Later official data shows 6,174 people had already developed symptoms by then,[323] and more may have been infected.[338] A report in The Lancet on 24 January indicated human transmission, strongly recommended personal protective equipment for health workers, and said testing for the virus was essential due to its "pandemic potential".[69][339] On 30 January, the WHO declared COVID-19 a Public Health Emergency of International Concern.[338] By this time, the outbreak spread by a factor of 100 to 200 times.[340]

Italy had its first confirmed cases on 31 January 2020, two tourists from China.[341] Italy overtook China as the country with the most deaths on 19 March 2020.[342] By 26 March the United States had overtaken China and Italy with the highest number of confirmed cases in the world.[343] Research on coronavirus genomes indicates the majority of COVID-19 cases in New York came from European travellers, rather than directly from China or any other Asian country.[344] Retesting of prior samples found a person in France who had the virus on 27 December 2019,[345][346] and a person in the United States who died from the disease on 6Template:NbsFebruary 2020.[347]

RT-PCR testing of untreated wastewater samples from Brazil and Italy have suggested detection of SARS-CoV-2 as early as November and December 2019, respectively, but the methods of such sewage studies have not been optimised, many have not been peer-reviewed, details are often missing, and there is a risk of false positives due to contamination or if only one gene target is detected.[348] A September 2020 review journal article said, "The possibility that the COVID‑19 infection had already spread to Europe at the end of last year is now indicated by abundant, even if partially circumstantial, evidence," including pneumonia case numbers and radiology in France and Italy in November and December.[349]

As of 1 October 2021, Reuters reported that it had estimated the worldwide total number of deaths due to COVID‑19 to have exceeded five million.[350]


After the initial outbreak of COVID‑19, misinformation and disinformation regarding the origin, scale, prevention, treatment, and other aspects of the disease rapidly spread online.[351][352][353]

In September 2020, the US Centers for Disease Control and Prevention (CDC) published preliminary estimates of the risk of death by age groups in the United States, but those estimates were widely misreported and misunderstood.[354][355]

Other species

Humans appear to be capable of spreading the virus to some other animals, a type of disease transmission referred to as zooanthroponosis.

Some pets, especially cats and ferrets, can catch this virus from infected humans.[356][357] Symptoms in cats include respiratory (such as a cough) and digestive symptoms.[356] Cats can spread the virus to other cats, and may be able to spread the virus to humans, but cat-to-human transmission of SARS-CoV-2 has not been proven.[356][358] Compared to cats, dogs are less susceptible to this infection.[358] Behaviours which increase the risk of transmission include kissing, licking, and petting the animal.[358]

The virus does not appear to be able to infect pigs, ducks, or chickens at all.[356] Mice, rats, and rabbits, if they can be infected at all, are unlikely to be involved in spreading the virus.[358]

Tigers and lions in zoos have become infected as a result of contact with infected humans.[358] As expected, monkeys and great ape species such as orangutans can also be infected with the COVID‑19 virus.[358]

Minks, which are in the same family as ferrets, have been infected.[358] Minks may be asymptomatic, and can also spread the virus to humans.[358] Multiple countries have identified infected animals in mink farms.[359] Denmark, a major producer of mink pelts, ordered the slaughter of all minks over fears of viral mutations,[359] following an outbreak referred to as Cluster 5. A vaccine for mink and other animals is being researched.[359]


International research on vaccines and medicines in COVID‑19 is underway by government organisations, academic groups, and industry researchers.[360][361] The CDC has classified it to require a BSL3 grade laboratory.[362] There has been a great deal of COVID‑19 research, involving accelerated research processes and publishing shortcuts to meet the global demand.[363]

As of December 2020, hundreds of clinical trials have been undertaken, with research happening on every continent except Antarctica.[364] As of November 2020, more than 200 possible treatments have been studied in humans.[365]

Transmission and prevention research

Modelling research has been conducted with several objectives, including predictions of the dynamics of transmission,[366] diagnosis and prognosis of infection,[367] estimation of the impact of interventions,[368][369] or allocation of resources.[370] Modelling studies are mostly based on compartmental models in epidemiology,[371] estimating the number of infected people over time under given conditions. Several other types of models have been developed and used during the COVID‑19 including computational fluid dynamics models to study the flow physics of COVID‑19,[372] retrofits of crowd movement models to study occupant exposure,[373] mobility-data based models to investigate transmission,[374] or the use of macroeconomic models to assess the economic impact of the pandemic.[375] Further, conceptual frameworks from crisis management research have been applied to better understand the effects of COVID‑19 on organisations worldwide.[376][377]

Treatment-related research

Seven possible drug targets in viral replication process and drugs

Repurposed antiviral drugs make up most of the research into COVID‑19 treatments.[378][379] Other candidates in trials include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2.[379]

In March 2020, the World Health Organization (WHO) initiated the Solidarity trial to assess the treatment effects of some promising drugs: an experimental drug called remdesivir; anti-malarial drugs chloroquine and hydroxychloroquine; two anti-HIV drugs, lopinavir/ritonavir; and interferon-beta.[380][381] More than 300 active clinical trials are underway as of April 2020.[125]

Research on the antimalarial drugs hydroxychloroquine and chloroquine showed that they were ineffective at best,[382][383] and that they may reduce the antiviral activity of remdesivir.[384] By May 2020, France, Italy, and Belgium had banned the use of hydroxychloroquine as a COVID‑19 treatment.[385]

In June, initial results from the randomised RECOVERY Trial in the United Kingdom showed that dexamethasone reduced mortality by one third for people who are critically ill on ventilators and one fifth for those receiving supplemental oxygen.[386] Because this is a well-tested and widely available treatment, it was welcomed by the WHO, which is in the process of updating treatment guidelines to include dexamethasone and other steroids.[387][388] Based on those preliminary results, dexamethasone treatment has been recommended by the NIH for patients with COVID‑19 who are mechanically ventilated or who require supplemental oxygen but not in patients with COVID‑19 who do not require supplemental oxygen.[389]

In September 2020, the WHO released updated guidance on using corticosteroids for COVID‑19.[390][391] The WHO recommends systemic corticosteroids rather than no systemic corticosteroids for the treatment of people with severe and critical COVID‑19 (strong recommendation, based on moderate certainty evidence).[390] The WHO suggests not to use corticosteroids in the treatment of people with non-severe COVID‑19 (conditional recommendation, based on low certainty evidence).[390] The updated guidance was based on a meta-analysis of clinical trials of critically ill COVID‑19 patients.[392][393]

In September 2020, the European Medicines Agency (EMA) endorsed the use of dexamethasone in adults and adolescents from twelve years of age and weighing at least 40 kilograms (88 lb) who require supplemental oxygen therapy.[394][395] Dexamethasone can be taken by mouth or given as an injection or infusion (drip) into a vein.[394]

In November 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID‑19.[396] Bamlanivimab is authorised for people with positive results of direct SARS-CoV-2 viral testing who are twelve years of age and older weighing at least 40 kilograms (88 lb), and who are at high risk for progressing to severe COVID‑19 or hospitalisation.[396] This includes those who are 65 years of age or older, or who have chronic medical conditions.[396]

In February 2021, the FDA issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID‑19 in people twelve years of age or older weighing at least 40 kilograms (88 lb) who test positive for SARS‑CoV‑2 and who are at high risk for progressing to severe COVID‑19. The authorised use includes treatment for those who are 65 years of age or older or who have certain chronic medical conditions.[397]

In April 2021, the FDA revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID‑19 in adults and certain paediatric patients.[398]

Cytokine storm

Various therapeutic strategies for targeting cytokine storm

A cytokine storm can be a complication in the later stages of severe COVID‑19. A cytokine storm is a potentially deadly immune reaction where a large amount of pro-inflammatory cytokines and chemokines are released too quickly. A cytokine storm can lead to ARDS and multiple organ failure.[399] Data collected from Jin Yin-tan Hospital in Wuhan, China indicates that patients who had more severe responses to COVID‑19 had greater amounts of pro-inflammatory cytokines and chemokines in their system than patients who had milder responses. These high levels of pro-inflammatory cytokines and chemokines indicate presence of a cytokine storm.[400]

Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.[401][402] It is undergoing a [[Phase IIb|PhaseTemplate:NbsII]] non-randomised trial at the national level in Italy after showing positive results in people with severe disease.[403][404] Combined with a serum ferritin blood test to identify a cytokine storm (also called cytokine storm syndrome, not to be confused with cytokine release syndrome), it is meant to counter such developments, which are thought to be the cause of death in some affected people.[405] The interleukin-6 receptor (IL-6R) antagonist was approved by the FDA to undergo a PhaseTemplate:NbsIII clinical trial assessing its effectiveness on COVID‑19 based on retrospective case studies for the treatment of steroid-refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.[406] There is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS. Prophylactic tocilizumab has been shown to increase serum IL-6 levels by saturating the IL-6R, driving IL-6 across the blood-brain barrier, and exacerbating neurotoxicity while having no effect on the incidence of CRS.[407]

Lenzilumab, an anti-GM-CSF monoclonal antibody, is protective in murine models for CAR T cell-induced CRS and neurotoxicity and is a viable therapeutic option due to the observed increase of pathogenic GM-CSF secreting TTemplate:Nbscells in hospitalised patients with COVID‑19.[408]

Passive antibodies

Overview of the application and use of convalescent plasma therapy

Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID‑19 to people who need them is being investigated as a non-vaccine method of passive immunisation.[409][410] Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2. The spike protein of SARS-CoV-2 is the primary target for neutralising antibodies.[411] As of 8Template:NbsAugust 2020, eight neutralising antibodies targeting the spike protein of SARS-CoV-2 have entered clinical studies.[412] It has been proposed that selection of broad-neutralising antibodies against SARS-CoV-2 and SARS-CoV might be useful for treating not only COVID‑19 but also future SARS-related CoV infections.[411] Other mechanisms, however, such as antibody-dependant cellular cytotoxicity or phagocytosis, may be possible.[409] Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.[409]

The use of passive antibodies to treat people with active COVID‑19 is also being studied. This involves the production of convalescent serum, which consists of the liquid portion of the blood from people who recovered from the infection and contains antibodies specific to this virus, which is then administered to active patients.[409] This strategy was tried for SARS with inconclusive results.[409] An updated Cochrane review in May 2021 found high certainty evidence that, for the treatment of people with moderate to severe COVID‑19, convalescent plasma did not reduce mortality or bring about symptom improvement.[410] There continues to be uncertainty about the safety of convalescent plasma administration to people with COVID‑19 and differing outcomes measured in different studies limits their use in determining efficacy.[410]


Since the outbreak of the COVID‑19 pandemic, scholars have explored the bioethics, normative economics, and political theories of healthcare policies related to the public health crisis.[413] Academics have pointed to the moral distress of healthcare workers, ethics of distributing scarce healthcare resources such as ventilators,[414] and the global justice of vaccine diplomacies.[citation needed] The socio-economic inequalities between genders,[415] races,[416] groups with disabilities,[417] communities,[418] regions, countries,[419] and continents have also drawn attention in academia and the general public.

Effects on other diseases

The use of social distancing and the wearing of surgical masks and similar precautions against COVID‑19 may have caused a drop in the spread of the common cold and the flu.[420][421]

See also


  1. "In Hunt for Covid-19 Origin, Patient Zero Points to Second Wuhan Market – The man with the first confirmed infection of the new coronavirus told the WHO team that his parents had shopped there". The Wall Street Journal. 26 February 2021. 
  2. "Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients". PLOS ONE 16 (4): e0249788. April 2021. Bibcode 2021PLoSO..1649788I. doi:10.1371/journal.pone.0249788. PMC 8023501. PMID 33822812. 
  3. "Prevalence of Headache in Patients With Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of 14,275 Patients". Frontiers in Neurology 11: 562634. November 2020. doi:10.3389/fneur.2020.562634. PMC 7728918. PMID 33329305. 
  4. "Prevalence of Olfactory Dysfunction in Coronavirus Disease 2019 (COVID-19): A Meta-analysis of 27,492 Patients". The Laryngoscope 131 (4): 865–878. April 2021. doi:10.1002/lary.29286. ISSN 0023-852X. PMC 7753439. PMID 33219539. 
  5. "Prevalence and Characteristics of Taste Disorders in Cases of COVID-19: A Meta-analysis of 29,349 Patients". Otolaryngology–Head and Neck Surgery 165 (1): 33–42. November 2020. doi:10.1177/0194599820981018. PMID 33320033. 
  6. "Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis". Mayo Clin. Proc. 95 (8): 1621–1631. August 2020. doi:10.1016/j.mayocp.2020.05.030. PMC 7275152. PMID 32753137. 
  7. "The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review". Annals of Internal Medicine 174 (5): M20-6976. January 2021. doi:10.7326/M20-6976. PMC 7839426. PMID 33481642. 
  8. {{#invoke:cite web||date=6 April 2020|title=Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)|url= March 2020|access-date=19 April 2020|website=U.S. Centers for Disease Control and Prevention (CDC)}}
  9. 9.0 9.1 {{#invoke:Cite web||last=CDC|date=11 February 2020|title=Post-COVID Conditions|url= July 2021|website=U.S. Centers for Disease Control and Prevention (CDC)}}
  10. {{#invoke:cite web||last=CDC|date=11 February 2020|title=Coronavirus Disease 2019 (COVID-19)|url= December 2020|website=U.S. Centers for Disease Control and Prevention (CDC)}}
  11. {{#invoke:cite web||title=Clinical Questions about COVID-19: Questions and Answers|website=U.S. Centers for Disease Control and Prevention (CDC)|date=17 November 2021|url= January 2022}}
  12. 12.0 12.1 12.2 {{#invoke:cite web||title=Overview of Testing for SARS-CoV-2, the virus that causes COVID-19|publisher=U.S. Centers for Disease Control and Prevention (CDC)|date=11 February 2020|url= July 2022}}
  13. 13.0 13.1 13.2 {{#invoke:cite web||title=Nucleic Acid Amplification Tests (NAATs)|publisher=U.S. Centers for Disease Control and Prevention (CDC)|date=11 February 2020|url= July 2022}}
  14. "High-Throughput Transcription-mediated amplification on the Hologic Panther is a highly sensitive method of detection for SARS-CoV-2". Journal of Clinical Virology 129: 104501. August 2020. doi:10.1016/j.jcv.2020.104501. PMC 7286273. PMID 32619959. 
  15. 15.0 15.1 15.2 15.3 15.4 "Laboratory diagnosis of coronavirus disease-2019 (COVID-19)". Clinica Chimica Acta; International Journal of Clinical Chemistry 510: 35–46. November 2020. doi:10.1016/j.cca.2020.06.045. PMC 7329657. PMID 32621814. 
  16. "2nd U.S. Case Of Wuhan Coronavirus Confirmed". NPR. 
  17. "Wuhan Coronavirus Looks Increasingly Like a Pandemic, Experts Say". The New York Times. 2 February 2020. ISSN 0362-4331. 
  18. "Wuhan coronavirus deaths spike again as outbreak shows no signs of slowing". CNN. 
  19. "A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome". Cellular & Molecular Immunology 17 (5): 554. May 2020. doi:10.1038/s41423-020-0372-4. PMC 7091741. PMID 32024976. 
  20. "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster". Lancet 395 (10223): 514–523. February 2020. doi:10.1016/S0140-6736(20)30154-9. PMC 7159286. PMID 31986261. 
  21. "The legacy of the Spanish flu". Science 357 (6357): 1245. September 2017. Bibcode 2017Sci...357.1245S. doi:10.1126/science.aao4093. ISSN 0036-8075. 
  22. "Stop the coronavirus stigma now". Nature 580 (7802): 165. 7 April 2020. Bibcode 2020Natur.580..165.. doi:10.1038/d41586-020-01009-0. PMID 32265571. Retrieved 16 April 2020. 
  23. {{#invoke:cite web||url= Coronavirus (2019-nCoV) Situation Report – 1|date=21 January 2020|website=World Health Organization (WHO)}}
  24. {{#invoke:cite web||url= Coronavirus(2019-nCoV) Situation Report – 10 |date=30 January 2020|website=World Health Organization (WHO)}}
  25. "Novel coronavirus named 'Covid-19': WHO". Today (Singapore). 
  26. "The coronavirus spreads racism against – and among – ethnic Chinese". The Economist. 17 February 2020. 
  27. Template:Cite report
  28. 28.0 28.1 {{#invoke:cite web||url= the coronavirus disease (COVID-19) and the virus that causes it|website=World Health Organization (WHO)|access-date=13 March 2020|archive-url= February 2020|url-status=live}}
  29. Template:Cite report
  30. "Anti-Asian Hate Crime During the COVID-19 Pandemic: Exploring the Reproduction of Inequality". American Journal of Criminal Justice 45 (4): 647–667. July 2020. doi:10.1007/s12103-020-09545-1. PMC 7364747. PMID 32837171. 
  31. "Characteristics of SARS-CoV-2 and COVID-19". Nature Reviews. Microbiology 19 (3): 141–154. March 2021. doi:10.1038/s41579-020-00459-7. PMC 7537588. PMID 33024307. 
  32. "Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): increased transmission beyond China – fourth update". European Centre for Disease Prevention and Control. 14 February 2020. 
  33. 33.0 33.1 "The proximal origin of SARS-CoV-2". Nature Medicine 26 (4): 450–452. April 2020. doi:10.1038/s41591-020-0820-9. PMC 7095063. PMID 32284615. 
  34. "Why soap is preferable to bleach in the fight against coronavirus". 18 March 2020. 
  35. "A Novel Coronavirus from Patients with Pneumonia in China, 2019". The New England Journal of Medicine 382 (8): 727–733. February 2020. doi:10.1056/NEJMoa2001017. PMC 7092803. PMID 31978945. 
  36. 36.0 36.1 36.2 Template:Cite report
  37. "Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)". World Health Organization (WHO). 
  38. "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview". Pathogens and Disease 78 (6). August 2020. doi:10.1093/femspd/ftaa042. OCLC 823140442. PMC 7499575. PMID 32840560. 
  39. "The Structure of the Membrane Protein of SARS-CoV-2 Resembles the Sugar Transporter SemiSWEET". Pathogens & Immunity 5 (1): 342–363. October 2020. doi:10.20411/pai.v5i1.377. PMC 7608487. PMID 33154981. 
  40. "Variant analysis of SARS-CoV-2 genomes". Bulletin of the World Health Organization 98 (7): 495–504. July 2020. doi:10.2471/BLT.20.253591. PMC 7375210. PMID 32742035. "We detected in total 65776 variants with 5775 distinct variants.". 
  41. 41.0 41.1 "A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology". Nature Microbiology 5 (11): 1403–1407. November 2020. doi:10.1038/s41564-020-0770-5. PMC 7610519. PMID 32669681. 
  42. "Tracking SARS-CoV-2 variants". 1 July 2021. 
  43. "Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020". Euro Surveillance 25 (32). August 2020. doi:10.2807/1560-7917.ES.2020.25.32.2001410. PMC 7427299. PMID 32794443. 
  44. "PANGO lineages". 
  45. "Genetic Variants of SARS-CoV-2-What Do They Mean?". JAMA 325 (6): 529–531. February 2021. doi:10.1001/jama.2020.27124. PMID 33404586. 
  46. "New SARS-CoV-2 Variants – Clinical, Public Health, and Vaccine Implications". The New England Journal of Medicine (Massachusetts Medical Society) 384 (19): 1866–1868. May 2021. doi:10.1056/nejmc2100362. ISSN 0028-4793. PMC 8008749. PMID 33761203. 
  47. "COVID mink analysis shows mutations are not dangerous – yet". Nature 587 (7834): 340–341. November 2020. Bibcode 2020Natur.587..340M. doi:10.1038/d41586-020-03218-z. PMID 33188367. 
  48. "Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread, Denmark, June to November 2020". Euro Surveillance 26 (5): 2100009. February 2021. doi:10.2807/1560-7917.ES.2021.26.5.210009. PMC 7863232. PMID 33541485. "As at 1 February 2021, we assess that the cluster 5 variant is no longer circulating among humans in Denmark.". 
  49. "New COVID-19 Variants". 28 June 2021. 
  50. "COVID-19 Weekly Epidemiological Update Edition 69". 7 December 2021. 
  51. "Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern". 
  52. "Mechanisms of SARS-CoV-2 Transmission and Pathogenesis". Trends in Immunology 41 (12): 1100–1115. December 2020. doi:10.1016/ PMC 7556779. PMID 33132005. 
  53. "The pivotal link between ACE2 deficiency and SARS-CoV-2 infection". European Journal of Internal Medicine 76: 14–20. June 2020. doi:10.1016/j.ejim.2020.04.037. PMC 7167588. PMID 32336612. 
  54. "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses". Nature Microbiology 5 (4): 562–569. April 2020. doi:10.1038/s41564-020-0688-y. PMC 7095430. PMID 32094589. 
  55. "A scoping review of the pathophysiology of COVID-19". International Journal of Immunopathology and Pharmacology 35: 20587384211048026. January 2021. doi:10.1177/20587384211048026. PMC 8477699. PMID 34569339. 
  56. 56.0 56.1 "COVID 19-Induced Smell and Taste Impairments: Putative Impact on Physiology". Frontiers in Physiology 11: 625110. June 2020. doi:10.3389/fphys.2020.625110. PMC 7870487. PMID 33574768. 
  57. "Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings". BMC Infectious Diseases 21 (1): 515. June 2021. doi:10.1186/s12879-021-06185-6. PMC 8170436. PMID 34078305. 
  58. 58.0 58.1 "Lifting the mask on neurological manifestations of COVID-19". Nature Reviews. Neurology 16 (11): 636–644. November 2020. doi:10.1038/s41582-020-0398-3. PMC 7444680. PMID 32839585. 
  59. "The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients". Journal of Medical Virology 92 (6): 552–555. June 2020. doi:10.1002/jmv.25728. PMC 7228394. PMID 32104915. 
  60. "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms". ACS Chemical Neuroscience 11 (7): 995–998. April 2020. doi:10.1021/acschemneuro.0c00122. PMC 7094171. PMID 32167747. 
  61. "Update on neurological manifestations of COVID-19". Life Sciences 257: 118063. September 2020. doi:10.1016/j.lfs.2020.118063. PMC 7346808. PMID 32652139. 
  62. Covid can shrink brain and damage its tissue, finds research The Guardian
  63. Scans reveal how Covid may change the brain BBC
  64. "Even mild Covid is linked to brain damage months after illness, scans show". NBC News. 
  65. "COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission". Gastroenterology 158 (6): 1518–1519. May 2020. doi:10.1053/j.gastro.2020.02.054. PMC 7130192. PMID 32142785. 
  66. "COVID-19, coronavirus, SARS-CoV-2 and the small bowel". Revista Espanola de Enfermedades Digestivas 112 (5): 383–388. May 2020. doi:10.17235/reed.2020.7137/2020. PMID 32343593. 
  67. "COVID-19-Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review". Clinical Microbiology and Infection 28 (8): 1066–1075. August 2022. doi:10.1016/j.cmi.2022.03.021. PMC 8941843. PMID 35339672. 
  68. 68.0 68.1 68.2 "COVID-19 and the cardiovascular system". Nature Reviews. Cardiology 17 (5): 259–260. May 2020. doi:10.1038/s41569-020-0360-5. PMC 7095524. PMID 32139904. 
  69. 69.0 69.1 69.2 "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet 395 (10223): 497–506. February 2020. doi:10.1016/S0140-6736(20)30183-5. PMC 7159299. PMID 31986264. 
  70. "Coronavirus disease 2019 (COVID-19): Myocardial infarction and other coronary artery disease issues". 
  71. "ACE2: from vasopeptidase to SARS virus receptor". Trends in Pharmacological Sciences 25 (6): 291–4. June 2004. doi:10.1016/ PMC 7119032. PMID 15165741. 
  72. "The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management". Thrombosis Research (Elsevier BV) 194: 101–115. October 2020. doi:10.1016/j.thromres.2020.06.029. PMC 7305763. PMID 32788101. 
  73. 73.0 73.1 73.2 "How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes". Science. April 2020. doi:10.1126/science.abc3208. 
  74. "NIH study uncovers blood vessel damage and inflammation in COVID-19 patients' brains but no infection". National Institutes of Health (NIH). 30 December 2020. 
  75. "Microvascular Injury in the Brains of Patients with Covid-19". The New England Journal of Medicine 384 (5): 481–483. February 2021. doi:10.1056/nejmc2033369. PMC 7787217. PMID 33378608. 
  76. "Physical phenotype of blood cells is altered in COVID-19". Biophysical Journal 120 (14): 2838–2847. July 2021. Bibcode 2021BpJ...120.2838K. doi:10.1016/j.bpj.2021.05.025. PMC 8169220. PMID 34087216. 
  77. "Extrapulmonary manifestations of COVID-19". Nature Medicine 26 (7): 1017–1032. July 2020. doi:10.1038/s41591-020-0968-3. PMID 32651579. 
  78. "Coronavirus: Kidney Damage Caused by COVID-19". 14 May 2020. 
  79. 79.0 79.1 79.2 79.3 79.4 79.5 79.6 79.7 "A Review of Postmortem Findings in Patients With COVID-19". Cureus (Cureus, Inc.) 12 (7): e9438. July 2020. doi:10.7759/cureus.9438. PMC 7451084. PMID 32864262. 
  80. "Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality". International Journal of Antimicrobial Agents 55 (5): 105954. May 2020. doi:10.1016/j.ijantimicag.2020.105954. PMC 7118634. PMID 32234467. 
  81. "Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy". Infection and Drug Resistance 13: 2485–2493. 2020. doi:10.2147/IDR.S258639. PMC 7383015. PMID 32801787. 
  82. "Viral targets for vaccines against COVID-19". Nature Reviews. Immunology 21 (2): 73–82. February 2021. doi:10.1038/s41577-020-00480-0. ISSN 1474-1733. PMC 7747004. PMID 33340022. 
  83. 83.0 83.1 "Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment". Journal of Biomolecular Structure & Dynamics 39 (9): 3409–3418. April 2020. doi:10.1080/07391102.2020.1758788. PMC 7196923. PMID 32306836. 
  84. "Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19". Hypertension Research 43 (7): 648–654. July 2020. doi:10.1038/s41440-020-0455-8. PMC 7184165. PMID 32341442. 
  85. "[Structure of SARS-CoV-2 and treatment of COVID-19]". Sheng Li Xue Bao 72 (5): 617–630. October 2020. PMID 33106832. 
  86. "Immunological considerations for COVID-19 vaccine strategies". Nature Reviews Immunology 20 (10): 615–632. 4 September 2020. doi:10.1038/s41577-020-00434-6. ISSN 1474-1741. PMC 7472682. PMID 32887954. 
  87. "Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2". Nature Communications 12 (1): 4210. July 2021. Bibcode 2021NatCo..12.4210Z. doi:10.1038/s41467-021-24514-w. PMC 8270942. PMID 34244522. 
  88. "Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment". Clinical Rheumatology 39 (7): 2085–2094. July 2020. doi:10.1007/s10067-020-05190-5. PMC 7260446. PMID 32474885. 
  89. "Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review". Journal of Medical Internet Research 22 (8): e20193. August 2020. doi:10.2196/20193. PMC 7428145. PMID 32707537. 
  90. "Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper". Frontiers in Immunology 11: 1648. 2020. doi:10.3389/fimmu.2020.01648. PMC 7365905. PMID 32754159. 
  91. 91.0 91.1 91.2 91.3 91.4 91.5 "Pregnancy and COVID-19". Physiological Reviews 101 (1): 303–318. January 2021. doi:10.1152/physrev.00024.2020. PMC 7686875. PMID 32969772. 
  92. "One in six most critically ill NHS Covid patients are unvaccinated pregnant women". 10 October 2021. 
  93. 93.0 93.1 "Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases". Radiology 296 (2): E32–E40. August 2020. doi:10.1148/radiol.2020200642. PMC 7233399. PMID 32101510. 
  94. 94.0 94.1 94.2 94.3 "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients". AJR. American Journal of Roentgenology 215 (1): 87–93. July 2020. doi:10.2214/AJR.20.23034. PMID 32174129. 
  95. "2019 Novel Coronavirus (2019-nCoV) Situation Summary". 30 January 2020. 
  96. "Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans". World Health Organization (WHO). 
  97. "Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples". Clinical Infectious Diseases 71 (10): 2663–2666. December 2020. doi:10.1093/cid/ciaa638. PMC 7314198. PMID 32442256. 
  98. "Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)". 11 February 2020. 
  99. "Real-Time RT-PCR Panel for Detection 2019-nCoV". 29 January 2020. 
  100. "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". 
  101. "NHS staff will be first to get new coronavirus antibody test, medical chief promises". 14 May 2020. 
  102. "Virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR". 1 September 2020. 
  103. "Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR". EBioMedicine 59: 102960. September 2020. doi:10.1016/j.ebiom.2020.102960. PMC 7444471. PMID 32853988. 
  104. "When is Covid, Covid?". 11 September 2020. 
  105. "SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence". 
  106. "ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection". 22 March 2020. 
  107. "Comparison of influenza type A and B with COVID-19: A global systematic review and meta-analysis on clinical, laboratory and radiographic findings". Reviews in Medical Virology 31 (3): e2179. October 2020. doi:10.1002/rmv.2179. PMC 7646051. PMID 33035373. 
  108. "COVID-19 pneumonia: what has CT taught us?". The Lancet. Infectious Diseases 20 (4): 384–385. April 2020. doi:10.1016/S1473-3099(20)30134-1. PMC 7128449. PMID 32105641. 
  109. 109.0 109.1 "Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management". AJR. American Journal of Roentgenology 214 (6): 1280–1286. June 2020. doi:10.2214/AJR.20.22954. PMID 32130038. 
  110. "COVID-19 Database" (in it). 
  111. "ICD-10 Version:2019". 2019. "U07.2Template:SndCOVID-19, virus not identifiedTemplate:SndCOVID-19 NOSTemplate:SndUse this code when COVID-19 is diagnosed clinically or epidemiologically but laboratory testing is inconclusive or not available. Use additional code, if desired, to identify pneumonia or other manifestations" 
  112. "Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe". Journal of Thoracic Oncology 15 (5): e65–e66. May 2020. doi:10.1016/j.jtho.2020.03.008. PMC 7118681. PMID 32194247. 
  113. "Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia". Journal of Thrombosis and Haemostasis 18 (4): 786–787. April 2020. doi:10.1111/jth.14781. PMC 7166410. PMID 32212240. 
  114. "Leukoerythroblastic reaction in a patient with COVID-19 infection". American Journal of Hematology 95 (8): 999–1000. August 2020. doi:10.1002/ajh.25793. PMC 7228283. PMID 32212392. 
  115. 115.0 115.1 115.2 115.3 115.4 115.5 "Postmortem Findings Associated With SARS-CoV-2: Systematic Review and Meta-analysis". The American Journal of Surgical Pathology 45 (5): 587–603. May 2021. doi:10.1097/PAS.0000000000001650. PMC 8132567. PMID 33481385. 
  116. "Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China". Science 368 (6492): 742–746. May 2020. arXiv:2002.07572. Bibcode 2020Sci...368..742M. doi:10.1126/science.abb4557. PMC 7164388. PMID 32269067.  ("...Template:Nbsinitial exponential growth expected for an unconstrained outbreak.")
  117. "Viral Load Exposure Factors". 
  118. "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". U.S. Centers for Disease Control and Prevention (CDC). 28 June 2020. 
  119. "Scientific Brief: SARS-CoV-2 and Potential Airborne Transmission". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. 
  120. "What to Do if You Are Sick". 5 April 2020. 
  121. "Coronavirus Disease 2019 (COVID-19) – Prevention & Treatment". U.S. Centers for Disease Control and Prevention (CDC). 10 March 2020. 
  122. "UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020. 
  123. "U.K. Approves Pfizer Coronavirus Vaccine, a First in the West". The New York Times. 2 December 2020. 
  124. "COVID-19 Treatment Guidelines". National Institutes of Health. 
  125. 125.0 125.1 125.2 "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review". JAMA 323 (18): 1824–1836. May 2020. doi:10.1001/jama.2020.6019. PMID 32282022. 
  126. 126.0 126.1 "How will country-based mitigation measures influence the course of the COVID-19 epidemic?". Lancet 395 (10228): 931–934. March 2020. doi:10.1016/S0140-6736(20)30567-5. PMC 7158572. PMID 32164834. "A key issue for epidemiologists is helping policy makers decide the main objectives of mitigationTemplate:Snde.g. minimising morbidity and associated mortality, avoiding an epidemic peak that overwhelms health-care services, keeping the effects on the economy within manageable levels, and flattening the epidemic curve to wait for vaccine development and manufacture on scale and antiviral drug therapies.". 
  127. "After 'Flatten the Curve', we must now 'Stop the Spread'. Here's what that means". 14 March 2020. 
  128. "Wear masks in public says WHO, in update of COVID-19 advice". Reuters. 5 June 2020. 
  129. 129.0 129.1 129.2 "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". 11 February 2020. 
  130. 130.0 130.1 "Using face masks in the community – Technical Report". 8 April 2020. 
  131. "Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2". 10 November 2020. 
  132. "Face masks for the public during the covid-19 crisis". BMJ 369: m1435. April 2020. doi:10.1136/bmj.m1435. PMID 32273267. 
  133. "Caring for Someone Sick at Home". 11 February 2020. 
  134. "Using Personal Protective Equipment (PPE)". 11 June 2020. 
  135. 135.0 135.1 135.2 CDC (11 February 2020). "Scientific Brief: SARS-CoV-2 Transmission". 
  136. "Transmission of COVID-19". European Centre for Disease Prevention and Control. 7 September 2020. 
  137. 137.0 137.1 "COVID-19 Employer Information for Office Buildings". 9 July 2020. 
  138. World Health Organization (29 October 2020). "WHO's Science in 5 on COVID-19 – Ventilation". 
  139. "Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission". The Lancet. Respiratory Medicine (Elsesier) 8 (7): 658–659. July 2020. doi:10.1016/S2213-2600(20)30245-9. PMC 7255254. PMID 32473123. 
  140. "Review of ventilation strategies to reduce the risk of disease transmission in high occupancy buildings". International Journal of Thermofluids 7–8: 100045. 1 November 2020. doi:10.1016/j.ijft.2020.100045. ISSN 2666-2027. 
  141. "Social distancing: what you need to do – Coronavirus (COVID-19)". 2 June 2020. 
  142. "Advice for the public on COVID-19 – World Health Organization". 
  143. "COVID-19 and Your Health". 11 February 2020. "To prevent the spread of germs, including COVID-19, CDC recommends washing hands with soap and water whenever possible because it reduces the amount of many types of germs and chemicals on hands. But if soap and water are not readily available, using a hand sanitizer with at least 60% alcohol can help you avoid getting sick and spreading germs to others." 
  144. "WHO-recommended handrub formulations". WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. World Health Organization (WHO). 19 March 2009. Retrieved 19 March 2020. 
  145. "Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review". The Cochrane Database of Systematic Reviews 2020 (9): CD013574. September 2020. doi:10.1002/14651858.CD013574.pub2. ISSN 1469-493X. PMC 8133397. PMID 33959956. 
  146. "COVID-19 and social distancing". Zeitschrift für Gesundheitswissenschaften = Journal of Public Health 30 (1): 259–261. May 2020. doi:10.1007/s10389-020-01321-z. PMC 7247774. PMID 32837835. 
  147. 147.0 147.1 "COVID-19 in Prisons and Jails in the United States". JAMA Internal Medicine 180 (8): 1041–1042. August 2020. doi:10.1001/jamainternmed.2020.1856. PMID 32343355. 
  148. "To Fight Virus in Prisons, C.D.C. Suggests More Screenings". 6 May 2020. 
  149. "How COVID-19 Spreads". 18 September 2020. 
  150. "Exaggerated risk of transmission of COVID-19 by fomites". The Lancet. Infectious Diseases 20 (8): 892–893. August 2020. doi:10.1016/S1473-3099(20)30561-2. PMC 7333993. PMID 32628907. 
  151. "CDC says risk of COVID-19 transmission on surfaces 1 in 10,000". 5 April 2021. 
  152. 152.0 152.1 "Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environments". 5 April 2021. 
  153. 153.0 153.1 "A Critical Review of Disinfection Processes to Control SARS-CoV-2 Transmission in the Food Industry". Foods 10 (2): 283. January 2021. doi:10.3390/foods10020283. PMC 7911259. PMID 33572531. 
  154. "Antimicrobial Resistance as a Hidden Menace Lurking Behind the COVID-19 Outbreak: The Global Impacts of Too Much Hygiene on AMR". Frontiers in Microbiology 11: 590683. 2020. doi:10.3389/fmicb.2020.590683. PMC 7769770. PMID 33384670. 
  155. "Hygiene Theater Is Still a Huge Waste of Time". 8 February 2021. 
  156. "Hygiene Theater Is a Huge Waste of Time". 27 July 2020. 
  157. 157.0 157.1 157.2 157.3 157.4 157.5 157.6 "Infectivity of SARS-CoV-2 and Other Coronaviruses on Dry Surfaces: Potential for Indirect Transmission". Materials 13 (22): 5211. November 2020. Bibcode 2020Mate...13.5211B. doi:10.3390/ma13225211. PMC 7698891. PMID 33218120. 
  158. "How coronavirus survives for days on surfaces". Physics of Fluids 32 (11): 111706. November 2020. Bibcode 2020PhFl...32k1706B. doi:10.1063/5.0033306. PMC 7713872. PMID 33281435. 
  159. "Why coronavirus survives longer on impermeable than porous surfaces". Physics of Fluids 33 (2): 021701. February 2021. Bibcode 2021PhFl...33b1701C. doi:10.1063/5.0037924. PMC 7978145. PMID 33746485. 
  160. CDC (11 February 2020). "Coronavirus Disease 2019 (COVID-19)". 
  161. "Has the Era of Overzealous Cleaning Finally Come to an End?". The New York Times. 8 April 2021. 
  162. "Interim Recommendations for US Community Facilities with Suspected/Confirmed Coronavirus Disease 2019". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. 
  163. "Yes, UV phone sanitizers work. That doesn't mean you need one.". The Washington Post. 16 February 2021. 
  164. "Non-pharmaceutical interventions for containment, mitigation and suppression of COVID-19 infection". Colombia Medica 51 (2): e4266. June 2020. doi:10.25100/cm.v51i2.4266. PMC 7518730. PMID 33012884. 
  165. "COVID-19 Informational Resources for High-Risk Groups | Keeping Education ACTIVE | Partnership to Fight Chronic Disease". 
  166. "Quarantine and Isolation". U.S. Centers for Disease Control and Prevention (CDC). 29 July 2021. 
  167. "Food safety, nutrition, and wellness during COVID-19". Harvard T.H. Chan School of Public Health. 29 May 2020. 
  168. "Regular Exercise May Help Protect Against Severe COVID". The New York Times. 14 April 2021. 
  169. "Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients". British Journal of Sports Medicine 55 (19): 1099–1105. April 2021. doi:10.1136/bjsports-2021-104080. PMC 8050880. PMID 33849909. 
  170. "Vitamin D supplementation to treat SARS-CoV-2 positive patients. Evidence from meta-analysis". Cardiology Journal 29 (2): 188–196. October 2021. doi:10.5603/CJ.a2021.0122. PMC 9007480. PMID 34642923. 
  171. "Trial to test if Vitamin D protects against Covid". BBC News. 13 October 2020. 
  172. 172.0 172.1 "Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections – Full Text View –". 
  173. 173.0 173.1 173.2 "International travel-related control measures to contain the COVID-19 pandemic: a rapid review". The Cochrane Database of Systematic Reviews 2021 (3): CD013717. March 2021. doi:10.1002/14651858.CD013717.pub2. PMC 8406796. PMID 33763851. 
  174. "Will covid-19 vaccines save lives? Current trials aren't designed to tell us". BMJ 371: m4037. October 2020. doi:10.1136/bmj.m4037. PMID 33087398. 
  175. 175.0 175.1 Template:Cite report
  176. "Dysnatremia is a Predictor for Morbidity and Mortality in Hospitalized Patients with COVID-19". The Journal of Clinical Endocrinology and Metabolism 106 (6): 1637–1648. May 2021. doi:10.1210/clinem/dgab107. PMC 7928894. PMID 33624101. 
  177. "MANAGEMENT OF ENDOCRINE DISEASE: Dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management". European Journal of Endocrinology 185 (4): R103–R111. September 2021. doi:10.1530/EJE-21-0281. PMC 8428074. PMID 34370712. 
  178. "Letter: Acid secretion by gastric mucous membrane". The American Journal of Physiology 229 (6): 21–25. December 1975. doi:10.1080/03007995.2020.1853510. PMC 7738209. PMID 33210948. 
  179. "Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19)". Seminars in Thrombosis and Hemostasis 46 (7): 845–849. October 2020. doi:10.1055/s-0040-1715458. PMC 7645834. PMID 32877961. 
  180. "Living with Covid19". NIHR Themed Reviews (National Institute for Health Research). 15 October 2020. doi:10.3310/themedreview_41169. 
  181. 181.0 181.1 "How long does COVID-19 last?". UK COVID Symptom Study. 6 June 2020. 
  182. "Summary of COVID-19 Long Term Health Effects: Emerging evidence and Ongoing Investigation". University of Washington. 1 September 2020. 
  183. "Long-term symptoms of COVID-19 'really concerning', says WHO chief". 30 October 2020. 
  184. "Coronavirus disease 2019 (COVID-19) – Prognosis". 
  185. "Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission – United States, March–August 2020". MMWR. Morbidity and Mortality Weekly Report 69 (45): 1695–1699. November 2020. doi:10.15585/mmwr.mm6945e2. PMC 7660660. PMID 33180754. 
  186. "COVID-19 and smoking: A systematic review of the evidence". Tobacco Induced Diseases 18: 20. March 2020. doi:10.18332/tid/119324. PMC 7083240. PMID 32206052. 
  187. 187.0 187.1 187.2 "Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking". Environmental Toxicology and Pharmacology 78: 103411. August 2020. doi:10.1016/j.etap.2020.103411. PMC 7227557. PMID 32422280. 
  188. "Potential role of particulate matter in the spreading of COVID-19 in Northern Italy: first observational study based on initial epidemic diffusion". BMJ Open 10 (9): e039338. September 2020. doi:10.1136/bmjopen-2020-039338. PMC 7517216. PMID 32973066. 
  189. "Air pollution and COVID-19 mortality in the United States: Strengths and limitations of an ecological regression analysis". Science Advances 6 (45): eabd4049. November 2020. Bibcode 2020SciA....6.4049W. doi:10.1126/sciadv.abd4049. PMC 7673673. PMID 33148655. 
  190. "Early Spread of COVID-19 in the Air-Polluted Regions of Eight Severely Affected Countries". Atmosphere 12 (6): 795. June 2021. Bibcode 2021Atmos..12..795P. doi:10.3390/atmos12060795. 
  191. "Air Pollution and Covid-19: The Role of Particulate Matter in the Spread and Increase of Covid-19's Morbidity and Mortality". International Journal of Environmental Research and Public Health 17 (12): 4487. June 2020. doi:10.3390/ijerph17124487. PMC 7345938. PMID 32580440. 
  192. "Influence of airborne transmission of SARS-CoV-2 on COVID-19 pandemic. A review". Environmental Research 188: 109861. September 2020. Bibcode 2020ER....188j9861D. doi:10.1016/j.envres.2020.109861. PMC 7309850. PMID 32718835. 
  193. "COVID-19: Who's at higher risk of serious symptoms?". 
  194. "Obesity as a predictor for a poor prognosis of COVID-19: A systematic review". Diabetes & Metabolic Syndrome 14 (4): 655–659. July 2020. doi:10.1016/j.dsx.2020.05.020. PMC 7217103. PMID 32438328. 
  195. "Obesity – A risk factor for increased COVID-19, severity and lethality (Review)". Molecular Medicine Reports 22 (1): 9–19. July 2020. doi:10.3892/mmr.2020.11127. PMC 7248467. PMID 32377709. 
  196. "Hepatic Steatosis, Rather Than Underlying Obesity, Increases the Risk of Infection and Hospitalization for COVID-19". Frontiers in Medicine 8: 636637. 29 March 2021. doi:10.3389/fmed.2021.636637. ISSN 2296-858X. PMC 8039134. PMID 33855033. 
  197. "Coronavirus Disease 2019 (COVID-19)". 11 February 2020. 
  198. "COVID-19 Infection in Kidney Transplant Recipients: A Single-Center Case Series of 22 Cases From Belgium". Kidney Medicine 2 (4): 459–466. November 2020. doi:10.1016/j.xkme.2020.06.001. PMC 7295531. PMID 32775986. 
  199. "Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity". Nature Genetics 53 (6): 801–808. April 2021. doi:10.1038/s41588-021-00854-7. PMID 33888907. 
  200. "One in Seven Dire COVID Cases May Result from a Faulty Immune Response". 
  201. "Autoantibodies against type I IFNs in patients with life-threatening COVID-19". Science 370 (6515): eabd4585. October 2020. doi:10.1126/science.abd4585. PMC 7857397. PMID 32972996. 
  202. "A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication". Gastroenterology 144 (7): 1438–49, 1449.e1-9. June 2013. doi:10.1053/j.gastro.2013.02.026. PMC 3665646. PMID 23462180. 
  203. Dhindsa, Sandeep; Champion, Cosette; Deol, Ekamjit; Lui, Matthew; Campbell, Robert; Newman, Jennifer; Yeggalam, Aparna; Nadella, Srikanth et al. (2022-09-02). "Association of Male Hypogonadism With Risk of Hospitalization for COVID-19". JAMA Network Open 5 (9): e2229747–e2229747. doi:10.1001/jamanetworkopen.2022.29747. ISSN 2574-3805. 
  204. "COVID-19 in children and the role of school settings in transmission – first update". 23 December 2020. 
  205. "Estimated Disease Burden of COVID-19". 11 February 2020. 
  206. "Why don't kids tend to get as sick from Covid-19?". Knowable Magazine. 2 September 2021. doi:10.1146/knowable-090121-1. Retrieved 7 September 2021. 
  207. "Information for Pediatric Healthcare Providers". 11 February 2020. 
  208. "COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study". The Lancet. Child & Adolescent Health 4 (9): 653–661. September 2020. doi:10.1016/S2352-4642(20)30177-2. PMC 7316447. PMID 32593339. 
  209. "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?". The Lancet. Respiratory Medicine 8 (4): e21. April 2020. doi:10.1016/S0140-6736(20)30311-1. PMC 7118626. PMID 32171062. 
  210. "Coronavirus Disease 2019 (COVID-19)". 11 February 2020. 
  211. "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China". International Journal of Infectious Diseases 91: 264–266. February 2020. doi:10.1016/j.ijid.2020.01.009. PMC 7128332. PMID 31953166. 
  212. "Care for Critically Ill Patients With COVID-19". JAMA 323 (15): 1499–1500. April 2020. doi:10.1001/jama.2020.3633. PMID 32159735. 
  213. "Features, Evaluation and Treatment Coronavirus (COVID-19)". StatPearls. Treasure Island (FL): StatPearls Publishing. 2020. PMID 32150360. Retrieved 18 March 2020. 
  214. "COVID-19: what is next for public health?". Lancet 395 (10224): 542–545. February 2020. doi:10.1016/s0140-6736(20)30374-3. PMC 7138015. PMID 32061313. 
  215. "Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis". Journal of Clinical Medicine 10 (11): 2490. June 2021. doi:10.3390/jcm10112490. PMC 8200114. PMID 34199857. 
  216. "Arrhythmia in patients with severe coronavirus disease (COVID-19): a meta-analysis". European Review for Medical and Pharmacological Sciences 24 (21): 11395–11401. November 2020. doi:10.26355/eurrev_202011_23632. PMID 33215461. 
  217. "Cardiovascular complications in COVID-19". The American Journal of Emergency Medicine 38 (7): 1504–1507. July 2020. doi:10.1016/j.ajem.2020.04.048. PMC 7165109. PMID 32317203. 
  218. "Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)". JAMA Cardiology 5 (11): 1265–1273. November 2020. doi:10.1001/jamacardio.2020.3557. PMC 7385689. PMID 32730619. 
  219. "Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases". JAMA Cardiology 5 (11): 1281–1285. November 2020. doi:10.1001/jamacardio.2020.3551. PMC 7385672. PMID 32730555. 
  220. "Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management". Heart Rhythm 17 (9): 1463–1471. September 2020. doi:10.1016/j.hrthm.2020.05.001. PMC 7199677. PMID 32387246. 
  221. "Liver injury during highly pathogenic human coronavirus infections". Liver International 40 (5): 998–1004. May 2020. doi:10.1111/liv.14435. PMC 7228361. PMID 32170806. 
  222. "Neurological complications of coronavirus and COVID-19". Revista de Neurología 70 (9): 311–322. May 2020. doi:10.33588/rn.7009.2020179. PMID 32329044. 
  223. "Guillain-Barré Syndrome Associated with SARS-CoV-2". The New England Journal of Medicine 382 (26): 2574–2576. June 2020. doi:10.1056/NEJMc2009191. PMC 7182017. PMID 32302082. 
  224. "Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19". 15 May 2020. 
  225. Template:Cite report
  226. "COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features". Radiology 296 (2): E119–E120. August 2020. doi:10.1148/radiol.2020201187. PMC 7233386. PMID 32228363. 
  227. 227.0 227.1 "COVID-19 y Embarazo" (in es). Medical Journal of Costa Rica: 629. April 2020. Retrieved 14 February 2022. 
  228. "Mucormycosis Following COVID-19 Infections: an Insight". The Indian Journal of Surgery 84 (3): 585–586. July 2021. doi:10.1007/s12262-021-03028-1. PMC 8270771. PMID 34276145. 
  229. "Mucormycosis and Aspergillosis have been Linked to Covid-19-Related Fungal Infections in India". Advancements in Case Studies 3 (1). June 2021. doi:10.31031/AICS.2021.03.000555. ISSN 2639-0531. 
  230. "Living with Covid19". NIHR Themed Review (National Institute for Health Research). 15 October 2020. doi:10.3310/themedreview_41169. 
  231. "Summary of COVID-19 Long Term Health Effects: Emerging evidence and Ongoing Investigation". University of Washington. 1 September 2020. 
  232. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet 395 (10223): 497–506. February 2020. doi:10.1016/S0140-6736(20)30183-5. PMC 7159299. PMID 31986264. 
  233. 233.0 233.1 "Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis". Pulmonology (Elsevier BV) 27 (4): 328–337. November 2020. doi:10.1016/j.pulmoe.2020.10.013. PMC 7687368. PMID 33262076. 
  234. "The lingering manifestations of COVID-19 during and after convalescence: update on long-term pulmonary consequences of coronavirus disease 2019 (COVID-19)". La Radiologia Medica 126 (1): 40–46. January 2021. doi:10.1007/s11547-020-01295-8. PMC 7529085. PMID 33006087. 
  235. "Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery". EClinicalMedicine 25: 100463. August 2020. doi:10.1016/j.ijtb.2020.11.003. PMC 7654356. PMID 32838236. 
  236. "COVID-19 Lung Damage". Johns Hopkins Medicine. 28 February 2022. 
  237. "Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients" (in English). The Lancet Psychiatry. 17 August 2022. doi:10.1016/S2215-0366(22)00260-7. ISSN 2215-0366. PMC 9385200. PMID 35987197. 
  238. "Immune responses and correlates of protective immunity against SARS-CoV-2". European Centre for Disease Prevention and Control. 18 May 2021. 
  239. "Immunology of COVID-19: Current State of the Science". Immunity 52 (6): 910–941. June 2020. doi:10.1016/j.immuni.2020.05.002. PMC 7200337. PMID 32505227. 
  240. "Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection". Nature 595 (7867): 426–431. July 2021. Bibcode 2021Natur.595..426W. doi:10.1038/s41586-021-03696-9. PMC 8277577. PMID 34126625. 
  241. 241.0 241.1 "Reinfection with SARS-CoV-2: Implications for Vaccines". Clinical Infectious Diseases 73 (11): e4223–e4228. December 2020. doi:10.1093/cid/ciaa1866. PMC 7799323. PMID 33338197. 
  242. 242.0 242.1 "COVID-19 reinfection: a rapid systematic review of case reports and case series". Journal of Investigative Medicine 69 (6): 1253–1255. August 2021. doi:10.1136/jim-2021-001853. ISSN 1081-5589. PMID 34006572. 
  243. 243.0 243.1 "How soon after catching COVID-19 can you get it again?". ABC News. 2 May 2022. 
  244. "Lesson 3: Measures of Risk Section 3: Mortality Frequency Measures". Principles of Epidemiology in Public Health Practice (Third ed.). U.S. Centers for Disease Control and Prevention (CDC). May 2012. No. SS1978. Retrieved 28 March 2020. 
  245. "What do we know about the risk of dying from COVID-19?". Our World in Data. 25 March 2020. Retrieved 28 March 2020. 
  246. "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review". JAMA Pediatrics 174 (9): 882–889. September 2020. doi:10.1001/jamapediatrics.2020.1467. PMID 32320004. 
  247. "SARS-CoV-2 Infection in Children". The New England Journal of Medicine (Massachusetts Medical Society) 382 (17): 1663–1665. April 2020. doi:10.1056/nejmc2005073. PMC 7121177. PMID 32187458. 
  248. "Epidemiology of COVID-19 Among Children in China". Pediatrics 145 (6): e20200702. June 2020. doi:10.1542/peds.2020-0702. PMID 32179660. 
  249. 249.0 249.1 249.2 249.3 "Sex differences in COVID-19 case fatality: do we know enough?". The Lancet. Global Health 9 (1): e14–e15. 2021. doi:10.1016/S2214-109X(20)30464-2. PMC 7834645. PMID 33160453. 
  250. "COVID-19 in Italy: momentous decisions and many uncertainties". The Lancet. Global Health 8 (5): e641–e642. May 2020. doi:10.1016/S2214-109X(20)30110-8. PMC 7104294. PMID 32199072. 
  251. "What do we know about the risk of dying from COVID-19?". Our World in Data. 5 March 2020. Retrieved 28 March 2020. 
  252. "Total confirmed cases of COVID-19 per million people". Template:Update inline
  253. "Cumulative confirmed COVID-19 deaths per million people". 
  254. "How deadly is the coronavirus? Scientists are close to an answer". Nature 582 (7813): 467–468. June 2020. Bibcode 2020Natur.582..467M. doi:10.1038/d41586-020-01738-2. PMID 32546810. 
  255. "Scientific consensus on the COVID-19 pandemic: we need to act now". Lancet 396 (10260): e71–e72. October 2020. doi:10.1016/S0140-6736(20)32153-X. PMC 7557300. PMID 33069277. 
  256. "A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates". International Journal of Infectious Diseases 101: 138–148. December 2020. doi:10.1016/j.ijid.2020.09.1464. PMC 7524446. PMID 33007452. 
  257. "Financial markets under the global pandemic of COVID-19". Finance Research Letters 36: 101528. October 2020. Bibcode 2020CSFX....500043D. doi:10.1016/j.csfx.2020.100043. PMC 7402242. PMID 32837360. 
  258. 258.0 258.1 258.2 258.3 258.4 "Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications". European Journal of Epidemiology 35 (12): 1123–1138. December 2020. doi:10.1007/s10654-020-00698-1. PMC 7721859. PMID 33289900.  50px Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
  259. World Health Organization (22 December 2020). Background paper on Covid-19 disease and vaccines: prepared by the Strategic Advisory Group of Experts (SAGE) on immunization working group on COVID-19 vaccines. 
  260. "Coronavirus disease 2019 (COVID-19) Situation Report – 30". 19 February 2020. 
  261. "Coronavirus disease 2019 (COVID-19) Situation Report – 31". 20 February 2020. 
  262. "The Pandemic's Big Mystery: How Deadly Is the Coronavirus? – Even with more than 500,000 dead worldwide, scientists are struggling to learn how often the virus kills. Here's why". The New York Times. 4 July 2020. 
  263. "Global Research and Innovation Forum on COVID-19: Virtual Press Conference". World Health Organization. 2 July 2020. 
  264. "Estimating mortality from COVID-19". 
  265. "Covid-19 still rife in Iran". New Scientist 252 (3357): 10–11. 23 October 2021. Bibcode 2021NewSc.252...10S. doi:10.1016/S0262-4079(21)01865-0. ISSN 0262-4079. PMC 8536311. PMID 34720322. 
  266. "COVID-19: Data". City of New York. 
  267. Template:Cite ssrn
  268. "Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis". The Lancet. Infectious Diseases 21 (2): 203–212. February 2021. doi:10.1016/s1473-3099(20)30769-6. PMC 7572090. PMID 33091374. 
  269. "How deadly is COVID-19? Data Science offers answers from Italy mortality data.". 21 April 2020. 
  270. "Coronavirus Disease 2019 (COVID-19)". 10 September 2020. 
  271. "Estimating the burden of SARS-CoV-2 in France". Science 369 (6500): 208–211. July 2020. Bibcode 2020Sci...369..208S. doi:10.1126/science.abc3517. PMC 7223792. PMID 32404476. 
  272. "Covid 19 Clinical Features". April 2021. 
  273. "Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission". Nature Communications 11 (1): 6317. December 2020. Bibcode 2020NatCo..11.6317P. doi:10.1038/s41467-020-19741-6. PMC 7726563. PMID 33298944. 
  274. "Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis". BMJ Open 10 (10): e040129. October 2020. doi:10.1136/bmjopen-2020-040129. PMC 7539579. PMID 33028563. 
  275. "The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)". China CDC Weekly 2 (8): 113–122. February 2020. doi:10.46234/ccdcw2020.032. ISSN 2096-7071. Retrieved 15 June 2020. 
  276. "Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis". Journal of Clinical Virology 127: 104371. June 2020. doi:10.1016/j.jcv.2020.104371. PMC 7195434. PMID 32315817. 
  277. "Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis". The Journal of Infection 80 (6): 656–665. June 2020. doi:10.1016/j.jinf.2020.03.041. PMC 7151416. PMID 32283155. 
  278. "COVID-19 pathophysiology: A review". Clinical Immunology 215: 108427. June 2020. doi:10.1016/j.clim.2020.108427. PMC 7169933. PMID 32325252. 
  279. "In Italy, Coronavirus Takes a Higher Toll on Men". The New York Times. 20 March 2020. 
  280. "COVID-19 weekly surveillance report". 
  281. 281.0 281.1 "Does Covid-19 Hit Women and Men Differently? U.S. Isn't Keeping Track". The New York Times. 3 April 2020. 
  282. 282.0 282.1 "COVID-19 exacerbating inequalities in the US". Lancet 395 (10232): 1243–1244. April 2020. doi:10.1016/S0140-6736(20)30893-X. PMC 7162639. PMID 32305087. 
  283. "Population-Based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States". Emerging Infectious Diseases 26 (8): 1831–1833. August 2020. doi:10.3201/eid2608.200679. PMC 7392427. PMID 32324118. 
  284. "Coronavirus y Desigualdades preexistentes: Género y Cuidados". 13 October 2020. 
  285. "COVID-19 Presents Significant Risks for American Indian and Alaska Native People". 14 May 2020. 
  286. "COVID-19 Presents Significant Risks for American Indian and Alaska Native People". 14 May 2020. 
  287. "The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities". Journal of Racial and Ethnic Health Disparities 7 (3): 398–402. June 2020. doi:10.1007/s40615-020-00756-0. PMC 7166096. PMID 32306369. 
  288. "How coronavirus deaths in the UK compare by race and ethnicity". 9 June 2020. 
  289. "Emerging findings on the impact of COVID-19 on black and minority ethnic people". The Health Foundation. 
  290. "Why are more BAME people dying from coronavirus?". BBC News. 9 June 2020. 
  291. 291.0 291.1 291.2 "The ancient Neanderthal hand in severe COVID-19". 30 September 2020. 
  292. "WHO Director-General's statement on the advice of the IHR Emergency Committee on Novel Coronavirus". 
  293. "Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1–30, 2020". MMWR. Morbidity and Mortality Weekly Report 69 (15): 458–464. April 2020. doi:10.15585/mmwr.mm6915e3. PMC 7755063. PMID 32298251. 
  294. "Coronavirus Disease 2019 (COVID-19)". 11 February 2020. 
  295. "The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis". Journal of Medical Virology 92 (10): 1915–1921. October 2020. doi:10.1002/jmv.25889. PMC 7262275. PMID 32293753. 
  296. "Smoking and COVID-19". 
  297. "Coronavirus Disease 2019 (COVID-19)". 11 February 2020. 
  298. "People who use drugs are more vulnerable to coronavirus. Here's what clinics are doing to help.". 3 May 2020. 
  299. "Coronavirus Disease 2019 (COVID-19)". 11 February 2020. 
  300. "Understanding the origin of COVID-19 requires to change the paradigm on zoonotic emergence from the spillover to the circulation model". Infection, Genetics and Evolution 95: 104812. November 2021. doi:10.1016/j.meegid.2021.104812. PMC 7969828. PMID 33744401. 
  301. "The origins of SARS-CoV-2: A critical review". Cell 184 (19): 4848–4856. September 2021. doi:10.1016/j.cell.2021.08.017. PMC 8373617. PMID 34480864. 
  302. "WHO-convened Global Study of Origins of SARS-CoV-2: China Part". World Health Organization. 30 March 2021. 
  303. "As the cases of coronavirus increase in China and around the world, the hunt is on to identify "patient zero".". BBC News. 24 February 2020. 
  304. "The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2". Science 377 (6609): 960–966. 26 July 2022. doi:10.1126/science.abp8337. PMC 9348752. PMID 35881005. 
  305. "Covid origin studies say evidence points to Wuhan market". 26 July 2022. 
  306. "The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic". Science 377 (6609): 951–959. July 2022. doi:10.1126/science.abp8715. PMC 9348750. PMID 35881010. 
  307. "Debate deepens over Wuhan wet market's role in kickstarting the pandemic". National Geographic. 27 July 2022. 
  308. "Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2". Journal of Medical Virology 92 (6): 602–611. June 2020. doi:10.1002/jmv.25731. PMC 7228310. PMID 32104911. 
  309. "The proximal origin of SARS-CoV-2". Nature Medicine 26 (4): 450–452. April 2020. doi:10.1038/s41591-020-0820-9. PMC 7095063. PMID 32284615. 
  310. "Emergence of genomic diversity and recurrent mutations in SARS-CoV-2". Infection, Genetics and Evolution 83: 104351. September 2020. doi:10.1016/j.meegid.2020.104351. PMC 7199730. PMID 32387564. 
  311. "Did the Coronavirus Originate Outside of Wuhan?". U.S. News & World Report. 13 May 2020. 
  312. "Analysis: Why scientists are suddenly more interested in the lab-leak theory of Covid's origin". CNN. 25 May 2021. 
  313. "US COVID origins report: researchers pleased with scientific approach". Nature 597 (7875): 159–160. September 2021. Bibcode 2021Natur.597..159M. doi:10.1038/d41586-021-02366-0. PMID 34465917. 
  314. "The outbreak of COVID-19: An overview". Journal of the Chinese Medical Association 83 (3): 217–220. March 2020. doi:10.1097/JCMA.0000000000000270. PMC 7153464. PMID 32134861. 
  315. "A novel coronavirus outbreak of global health concern". Lancet 395 (10223): 470–473. February 2020. doi:10.1016/S0140-6736(20)30185-9. PMC 7135038. PMID 31986257. 
  316. "Wuhan seafood market may not be source of novel virus spreading globally". Science. January 2020. doi:10.1126/science.abb0611. 
  317. "Novel Coronavirus – China". 12 January 2020. 
  318. "Trump's false claim that the WHO said the coronavirus was 'not communicable'". The Washington Post. 17 April 2020. 
  319. "China confirms human-to-human transmission of coronavirus". The Guardian. 21 January 2020. 
  320. Epidemiology Working Group For Ncip Epidemic Response; Chinese Center for Disease Control Prevention (February 2020). "[The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]" (in zh). Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi 41 (2): 145–151. doi:10.3760/cma.j.issn.0254-6450.2020.02.003. PMID 32064853. 
  321. "China Rules Out Animal Market and Lab as Coronavirus Origin". The Wall Street Journal. 26 May 2020. 
  322. "Italy sewage study suggests COVID-19 was there in December 2019". Reuters. 19 June 2020. 
  323. 323.0 323.1 "The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) – China, 2020". China CDC Weekly 2 (8): 113–122. February 2020. doi:10.46234/ccdcw2020.032. PMC 839292. PMID 34594836. 
  324. "COVID-19: what is next for public health?". Lancet 395 (10224): 542–545. February 2020. doi:10.1016/S0140-6736(20)30374-3. PMC 7138015. PMID 32061313. 
  325. "1st known case of coronavirus traced back to November in China". 14 March 2020. 
  326. Canadian Politics (8 April 2020). "The birth of a pandemic: How COVID-19 went from Wuhan to Toronto | National Post". National Post. 
  327. 高昱 (26 February 2020). "独家 | 新冠病毒基因测序溯源:警报是何时拉响的" (in zh). Caixin. 
  328. "最早上报疫情的她,怎样发现这种不一样的肺炎" (in zh-cn). 北京. 
  329. "Undiagnosed pneumonia – China (HU): RFI". ProMED. 
  330. "'Hero who told the truth': Chinese rage over coronavirus death of whistleblower doctor". The Guardian. 7 February 2020. 
  331. "Coronavirus: Wuhan doctor speaks out against authorities". The Guardian (London). 11 March 2020. 
  332. "Novel Coronavirus". World Health Organization (WHO). 
  333. "武汉现不明原因肺炎 官方确认属实:已经做好隔离". Xinhua Net 新華網. 31 December 2019. 
  334. "Error: no |title= specified when using {{Cite web}}" (in zh). Wuhan Municipal Health Commission. 31 December 2019. 
  335. "Mystery pneumonia virus probed in China". BBC News. 3 January 2020. 
  336. "Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia". The New England Journal of Medicine 382 (13): 1199–1207. March 2020. doi:10.1056/NEJMoa2001316. PMC 7121484. PMID 31995857. 
  337. "China confirms sharp rise in cases of SARS-like virus across the country". 20 January 2020. 
  338. 338.0 338.1 "Flattery and foot dragging: China's influence over the WHO under scrutiny". The Globe and Mail. 25 April 2020. 
  339. "Scientists have been sounding the alarm on coronavirus for months. Why did Britain fail to act?". 18 March 2020. 
  340. "China delayed releasing coronavirus info, frustrating WHO". Associated Press. 2 June 2020. 
  341. "Coronavirus: Primi due casi in Italia" (in it). Corriere della sera. 31 January 2020. 
  342. "Coronavirus: Number of COVID-19 deaths in Italy surpasses China as total reaches 3,405". Sky News. 
  343. "The U.S. Now Leads the World in Confirmed Coronavirus Cases". The New York Times. 26 March 2020. 
  344. "Studies Show N.Y. Outbreak Originated in Europe". The New York Times. 8 April 2020. 
  345. "After retesting samples, French hospital discovers COVID-19 case from December". Reuters. 4 May 2020. 
  346. "SARS-CoV-2 was already spreading in France in late December 2019". International Journal of Antimicrobial Agents 55 (6): 106006. June 2020. doi:10.1016/j.ijantimicag.2020.106006. PMC 7196402. PMID 32371096. 
  347. "2 died with coronavirus weeks before 1st U.S. virus death". 22 April 2020. 
  348. "Sewage analysis as a tool for the COVID-19 pandemic response and management: the urgent need for optimised protocols for SARS-CoV-2 detection and quantification". Journal of Environmental Chemical Engineering 8 (5): 104306. October 2020. doi:10.1016/j.jece.2020.104306. PMC 7384408. PMID 32834990. 
  349. "COVID19: an announced pandemic". Cell Death & Disease 11 (9): 799. September 2020. doi:10.1038/s41419-020-02995-9. PMC 7513903. PMID 32973152. 
  350. "Global COVID-19 deaths hit 5 million as Delta variant sweeps the world". Reuters. 3 October 2021. 
  351. "China coronavirus: Misinformation spreads online about origin and scale". BBC News. 30 January 2020. 
  352. "Bat soup, dodgy cures and 'diseasology': the spread of coronavirus misinformation". The Guardian. 31 January 2020. 
  353. "Here's A Running List Of Disinformation Spreading About The Coronavirus". 
  354. "Coronavirus Disease 2019 (COVID-19)". 11 February 2020. 
  355. "Misleading claim circulates online about infection fatality ratio of Covid-19 in the US". 8 October 2020. 
  356. 356.0 356.1 356.2 356.3 "Potential sources, modes of transmission and effectiveness of prevention measures against SARS-CoV-2". The Journal of Hospital Infection 106 (4): 678–697. December 2020. doi:10.1016/j.jhin.2020.09.022. PMC 7500278. PMID 32956786. 
  357. "Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2". Science 368 (6494): 1016–1020. May 2020. doi:10.1126/science.abb7015. PMC 7164390. PMID 32269068. 
  358. 358.0 358.1 358.2 358.3 358.4 358.5 358.6 358.7 "Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review". Journal of Translational Medicine 18 (1): 358. September 2020. doi:10.1186/s12967-020-02534-2. PMC 7503431. PMID 32957995. 
  359. 359.0 359.1 359.2 "The Coronavirus Kills Mink, So They Too May Get a Vaccine". The New York Times. 22 January 2021. ISSN 0362-4331. 
  360. "COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics". Human Vaccines & Immunotherapeutics 16 (6): 1232–1238. June 2020. doi:10.1080/21645515.2020.1735227. PMC 7103671. PMID 32186952. 
  361. "Potential interventions for novel coronavirus in China: A systematic review". Journal of Medical Virology 92 (5): 479–490. May 2020. doi:10.1002/jmv.25707. PMC 7166986. PMID 32052466. 
  362. "Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. 
  363. "A Bibliometric Analysis of COVID-19 across Science and Social Science Research Landscape". Sustainability 12 (21): 9132. November 2020. doi:10.3390/su12219132. 
  364. "First-of-its-kind African trial tests common drugs to prevent severe COVID-19". Science. 3 December 2020. doi:10.1126/science.abf9987. Retrieved 8 March 2022. 
  365. "Early dynamics of transmission and control of COVID-19: a mathematical modelling study". The Lancet. Infectious Diseases 20 (5): 553–558. May 2020. doi:10.1016/S1473-3099(20)30144-4. PMC 7158569. PMID 32171059. 
  366. "Update to living systematic review on prediction models for diagnosis and prognosis of covid-19". BMJ (Clinical Research Ed.) 372: n236. 3 February 2021. doi:10.1136/bmj.n236. ISSN 1756-1833. PMID 33536183. 
  367. "Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy". Nature Medicine 26 (6): 855–860. June 2020. arXiv:2003.09861. doi:10.1038/s41591-020-0883-7. PMC 7175834. PMID 32322102. 
  368. "The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study". The Lancet. Public Health 5 (5): e261–e270. May 2020. doi:10.1016/S2468-2667(20)30073-6. PMC 7158905. PMID 32220655. 
  369. "Fair Allocation of Scarce Medical Resources in the Time of Covid-19". The New England Journal of Medicine 382 (21): 2049–2055. May 2020. doi:10.1056/NEJMsb2005114. PMID 32202722. 
  370. "A contribution to the mathematical theory of epidemics". Proceedings of the Royal Society of London. Series A, Containing Papers of a Mathematical and Physical Character 115 (772): 700–721. 1927. Bibcode 1927RSPSA.115..700K. doi:10.1098/rspa.1927.0118. 
  371. "The flow physics of COVID-19". Journal of Fluid Mechanics 894: –2. 2020. arXiv:2004.09354. Bibcode 2020JFM...894F...2M. doi:10.1017/jfm.2020.330. 
  372. "EXPOSED: An occupant exposure model for confined spaces to retrofit crowd models during a pandemic". Safety Science 130: 104834. October 2020. arXiv:2005.04007. doi:10.1016/j.ssci.2020.104834. PMC 7373681. PMID 32834509. 
  373. "Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study". The Lancet Infectious Diseases 20 (11): 1247–1254. November 2020. doi:10.1016/S1473-3099(20)30553-3. PMC 7329287. PMID 32621869. 
  374. "The global macroeconomic impacts of COVID-19: Seven scenarios". CAMA Working Paper. 2020. doi:10.2139/ssrn.3547729. 
  375. "Crises and crisis management: Integration, interpretation, and research development.". Journal of Management 43 (6): 1661–92. July 2017. doi:10.1177/0149206316680030. 
  376. "The economics of COVID-19: initial empirical evidence on how family firms in five European countries cope with the corona crisis". International Journal of Entrepreneurial Behavior & Research 26 (5): 1067–1092. 2020. doi:10.1108/IJEBR-04-2020-0214. ISSN 1355-2554. 
  377. "COVID-19 treatment and vaccine tracker". Milken Institute. 21 April 2020. 
  378. 379.0 379.1 "First up for COVID-19: nearly 30 clinical readouts before end of April". BioCentury Inc.. 13 March 2020. 
  379. "WHO launches global megatrial of the four most promising coronavirus treatments". Science. March 2020. doi:10.1126/science.abb8497. 
  380. "UN health chief announces global 'solidarity trial' to jumpstart search for COVID-19 treatment". 18 March 2020. 
  381. "Citing safety concerns, the W.H.O. paused tests of a drug Trump said he had taken". The New York Times. 26 May 2020. 
  382. "Hydroxychloroquine does not benefit adults hospitalized with COVID-19" (Press release). 9 November 2020.  Template:PD-notice
  383. "Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use" (Press release). 15 June 2020.  Template:PD-notice
  384. "France bans use of hydroxychloroquine, drug touted by Trump, in coronavirus patients". CBS News. 27 May 2020. 
  385. "Recovery trial for Covid-19 treatments: what we know so far". The Guardian. 16 June 202. 
  386. "WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients" (Press release). 16 June 2020. 
  387. "Q&A: Dexamethasone and COVID-19" (Press release). 
  388. "Corticosteroids". National Institutes of Health. 
  389. 390.0 390.1 390.2 Template:Cite report
  390. "WHO updates clinical care guidance with corticosteroid recommendations". World Health Organization (WHO). 
  391. "Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis". JAMA 324 (13): 1330–1341. October 2020. doi:10.1001/jama.2020.17023. PMC 7489434. PMID 32876694. 
  392. "Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic". JAMA 324 (13): 1292–1295. October 2020. doi:10.1001/jama.2020.16747. PMID 32876693. 
  393. 394.0 394.1 "EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation" (Press release). 18 September 2020.  Text was copied from this source which is European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  394. Template:Cite report
  395. 396.0 396.1 396.2 "Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19" (Press release). 9 November 2020.  Template:PD-notice
  396. "FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19" (Press release). 10 February 2021.  Template:PD-notice
  397. "Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab" (Press release). 16 April 2021.  Template:PD-notice
  398. "Molecular immune pathogenesis and diagnosis of COVID-19". Journal of Pharmaceutical Analysis 10 (2): 102–108. April 2020. doi:10.1016/j.jpha.2020.03.001. PMC 7104082. PMID 32282863. 
  399. "An enlightening role for cytokine storm in coronavirus infection". Clinical Immunology 222: 108615. January 2021. doi:10.1016/j.clim.2020.108615. PMC 7583583. PMID 33203513. 
  400. "China approves use of Roche drug in battle against coronavirus complications". Reuters. 3 March 2020. 
  401. "Effective treatment of severe COVID-19 patients with tocilizumab". Proceedings of the National Academy of Sciences of the United States of America 117 (20): 10970–10975. May 2020. doi:10.1073/pnas.2005615117. PMC 7245089. PMID 32350134. 
  402. "COVID-19 – Italy launches an independent trial on tocilizumab". Aptus Health. 
  403. "Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19)". 
  404. Various sources:
  405. "FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia". Cancer Network. 26 March 2020. 
  406. "Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory, Aggressive Non-Hodgkin Lymphoma (NHL)". Blood 130 (Supplement 1): 1547. 2017. doi:10.1182/blood.V130.Suppl_1.1547.1547. 
  407. "GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR T cell function in xenografts". Blood 133 (7): 697–709. February 2019. doi:10.1182/blood-2018-10-881722. PMC 6376281. PMID 30463995. 
  408. 409.0 409.1 409.2 409.3 409.4 "The convalescent sera option for containing COVID-19". The Journal of Clinical Investigation 130 (4): 1545–1548. April 2020. doi:10.1172/JCI138003. PMC 7108922. PMID 32167489. 
  409. 410.0 410.1 410.2 "Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review". The Cochrane Database of Systematic Reviews 2021 (5): CD013600. May 2021. doi:10.1002/14651858.CD013600.pub4. PMC 8135693. PMID 34013969. 
  410. 411.0 411.1 "Perspectives on the development of neutralizing antibodies against SARS-CoV-2". Antibody Therapeutics 3 (2): 109–114. April 2020. doi:10.1093/abt/tbaa009. PMC 7291920. PMID 32566896. 
  411. "COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19". Antibody Therapeutics 3 (3): 205–212. July 2020. doi:10.1093/abt/tbaa020. PMC 7454247. PMID 33215063. 
  412. "The role of ethics in science: a systematic literature review from the first wave of COVID-19". Health and Technology 11 (5): 1063–1071. June 2021. doi:10.1007/s12553-021-00570-6. ISSN 2190-7188. PMC 8175060. PMID 34104626. 
  413. "Ethical Challenges Arising in the COVID-19 Pandemic: An Overview from the Association of Bioethics Program Directors (ABPD) Task Force". The American Journal of Bioethics 20 (7): 15–27. July 2020. doi:10.1080/15265161.2020.1764138. PMID 32511078. 
  414. "COVID-19: the gendered impacts of the outbreak". Lancet 395 (10227): 846–848. March 2020. doi:10.1016/S0140-6736(20)30526-2. PMC 7124625. PMID 32151325. 
  415. "Triage and justice in an unjust pandemic: ethical allocation of scarce medical resources in the setting of racial and socioeconomic disparities". Journal of Medical Ethics 47 (3): 200–202. October 2020. doi:10.1136/medethics-2020-106457. PMID 33067315. 
  416. "Disability, Ethics, and Health Care in the COVID-19 Pandemic". American Journal of Public Health 110 (10): 1523–1527. October 2020. doi:10.2105/AJPH.2020.305837. PMC 7483109. PMID 32816541. 
  417. "US-county level variation in intersecting individual, household and community characteristics relevant to COVID-19 and planning an equitable response: a cross-sectional analysis". BMJ Open 10 (9): e039886. September 2020. doi:10.1136/bmjopen-2020-039886. PMC 7467554. PMID 32873684. 
  418. "The trouble with trust: Time-series analysis of social capital, income inequality, and COVID-19 deaths in 84 countries". Social Science & Medicine 263: 113365. October 2020. doi:10.1016/j.socscimed.2020.113365. PMC 7492158. PMID 32981770. 
  419. "Pandemic sends demand for cold and flu remedies to record low". 2 March 2021. 
  420. "2020–2021 Flu Season Summary". U.S. Centers for Disease Control and Prevention (CDC). 25 October 2021. 

Further reading

External links


Health agencies


Medical journals

Treatment guidelines

{{#invoke:subject bar|main}}

Template:Medical resources Template:COVID-19 pandemic Template:Respiratory pathology Template:Viral diseases